0001938046 2024-01-01 2024-06-30 0001938046 dei:BusinessContactMember 2024-01-01 2024-06-30 0001938046 2023-12-31 0001938046 2022-12-31 0001938046 us-gaap:RelatedPartyMember 2023-12-31 0001938046 us-gaap:RelatedPartyMember 2022-12-31 0001938046 us-gaap:NonrelatedPartyMember 2023-12-31 0001938046 us-gaap:NonrelatedPartyMember 2022-12-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2023-12-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2022-12-31 0001938046 MGRX:SeriesCConvertiblePreferredStockMember 2023-12-31 0001938046 MGRX:SeriesCConvertiblePreferredStockMember 2022-12-31 0001938046 2024-06-30 0001938046 us-gaap:RelatedPartyMember 2024-06-30 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2024-06-30 0001938046 MGRX:SeriesCConvertiblePreferredStockMember 2024-06-30 0001938046 2023-01-01 2023-12-31 0001938046 2022-01-01 2022-12-31 0001938046 2024-04-01 2024-06-30 0001938046 2023-04-01 2023-06-30 0001938046 2023-01-01 2023-06-30 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2021-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2021-12-31 0001938046 us-gaap:CommonStockMember 2021-12-31 0001938046 us-gaap:WarrantMember 2021-12-31 0001938046 MGRX:SubscriptionReceivableMember 2021-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001938046 us-gaap:RetainedEarningsMember 2021-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2021-12-31 0001938046 2021-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2022-12-31 0001938046 us-gaap:CommonStockMember 2022-12-31 0001938046 us-gaap:WarrantMember 2022-12-31 0001938046 MGRX:SubscriptionReceivableMember 2022-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001938046 us-gaap:RetainedEarningsMember 2022-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2022-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-03-31 0001938046 us-gaap:CommonStockMember 2023-03-31 0001938046 us-gaap:WarrantMember 2023-03-31 0001938046 MGRX:SubscriptionReceivableMember 2023-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001938046 us-gaap:RetainedEarningsMember 2023-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2023-03-31 0001938046 2023-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-12-31 0001938046 us-gaap:CommonStockMember 2023-12-31 0001938046 us-gaap:WarrantMember 2023-12-31 0001938046 MGRX:SubscriptionReceivableMember 2023-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001938046 us-gaap:RetainedEarningsMember 2023-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2023-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2024-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2024-03-31 0001938046 us-gaap:CommonStockMember 2024-03-31 0001938046 us-gaap:WarrantMember 2024-03-31 0001938046 MGRX:SubscriptionReceivableMember 2024-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001938046 us-gaap:RetainedEarningsMember 2024-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2024-03-31 0001938046 2024-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001938046 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001938046 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001938046 MGRX:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001938046 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001938046 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001938046 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001938046 MGRX:SubscriptionReceivableMember 2023-01-01 2023-12-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001938046 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001938046 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001938046 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001938046 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001938046 MGRX:SubscriptionReceivableMember 2023-01-01 2023-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001938046 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001938046 2023-01-01 2023-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001938046 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001938046 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001938046 MGRX:SubscriptionReceivableMember 2023-04-01 2023-06-30 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001938046 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001938046 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001938046 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001938046 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001938046 MGRX:SubscriptionReceivableMember 2024-01-01 2024-03-31 0001938046 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001938046 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001938046 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001938046 2024-01-01 2024-03-31 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001938046 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001938046 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001938046 MGRX:SubscriptionReceivableMember 2024-04-01 2024-06-30 0001938046 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001938046 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001938046 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2023-06-30 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2023-06-30 0001938046 us-gaap:CommonStockMember 2023-06-30 0001938046 us-gaap:WarrantMember 2023-06-30 0001938046 MGRX:SubscriptionReceivableMember 2023-06-30 0001938046 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001938046 us-gaap:RetainedEarningsMember 2023-06-30 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001938046 us-gaap:NoncontrollingInterestMember 2023-06-30 0001938046 2023-06-30 0001938046 us-gaap:PreferredClassBMember us-gaap:PreferredStockMember 2024-06-30 0001938046 MGRX:PreferredClassCMember us-gaap:PreferredStockMember 2024-06-30 0001938046 us-gaap:CommonStockMember 2024-06-30 0001938046 us-gaap:WarrantMember 2024-06-30 0001938046 MGRX:SubscriptionReceivableMember 2024-06-30 0001938046 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001938046 us-gaap:RetainedEarningsMember 2024-06-30 0001938046 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001938046 us-gaap:NoncontrollingInterestMember 2024-06-30 0001938046 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0001938046 us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001938046 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001938046 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001938046 us-gaap:IPOMember 2023-02-28 2023-03-31 0001938046 us-gaap:IPOMember 2023-03-31 0001938046 MGRX:ResaleProspectusMember 2023-02-28 2023-03-31 0001938046 MGRX:ResaleProspectusMember 2023-03-31 0001938046 MGRX:UnderwritingAgreementMember MGRX:BousteadSecuritiesLLCMember 2023-12-15 2023-12-15 0001938046 us-gaap:CommonStockMember MGRX:UnderwritingAgreementMember 2023-12-15 0001938046 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember MGRX:UnderwritingAgreementMember 2023-12-15 2023-12-15 0001938046 us-gaap:CommonStockMember 2023-12-19 2023-12-19 0001938046 us-gaap:WarrantMember MGRX:UnderwritingAgreementMember 2023-12-19 0001938046 MGRX:UnderwritingAgreementMember 2023-12-19 0001938046 MGRX:UnderwritersMember 2024-01-18 2024-01-18 0001938046 MGRX:UnderwritersMember us-gaap:OverAllotmentOptionMember 2024-01-18 2024-01-18 0001938046 MGRX:UnderwritingAgreementMember 2024-01-22 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-05 2024-04-05 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-05 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-05 2024-04-05 0001938046 MGRX:EquityPurchaseAgreementMember 2024-04-05 2024-04-05 0001938046 MGRX:CommitmentSharesMember MGRX:EquityPurchaseAgreementMember 2024-04-05 0001938046 MGRX:CommitmentSharesMember MGRX:EquityPurchaseAgreementMember 2024-04-05 2024-04-05 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-26 2024-04-26 0001938046 us-gaap:SeriesBPreferredStockMember MGRX:SecuritiesPurchaseAgreementMember 2024-05-17 2024-05-17 0001938046 MGRX:ThridClosingDateMember us-gaap:SeriesBPreferredStockMember 2024-06-28 2024-06-28 0001938046 MGRX:ThridClosingDateMember MGRX:WarrantOneMember 2024-06-28 0001938046 MGRX:ThridClosingDateMember MGRX:WarrantTwoMember 2024-06-28 0001938046 us-gaap:SeriesBPreferredStockMember 2024-06-28 2024-06-28 0001938046 us-gaap:SeriesCPreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 2024-04-24 0001938046 us-gaap:SeriesCPreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 0001938046 MGRX:MangoRxMexicoMember 2024-06-30 0001938046 MGRX:MangoRxUKLimitedMember 2024-06-30 0001938046 MGRX:OptionsMember 2023-01-01 2023-12-31 0001938046 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001938046 MGRX:OptionsMember 2022-01-01 2022-12-31 0001938046 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001938046 srt:MinimumMember 2023-12-31 0001938046 srt:MaximumMember 2023-12-31 0001938046 MGRX:MangoRxUKLimitedMember MGRX:MangoRxIPHoldingsLLCMember 2024-06-30 0001938046 MGRX:OptionsMember 2024-01-01 2024-06-30 0001938046 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001938046 us-gaap:DerivativeMember 2024-01-01 2024-06-30 0001938046 us-gaap:DerivativeMember 2023-01-01 2023-12-31 0001938046 srt:MinimumMember 2024-06-30 0001938046 srt:MaximumMember 2024-06-30 0001938046 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001938046 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001938046 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001938046 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001938046 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001938046 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001938046 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001938046 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001938046 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001938046 2022-10-01 0001938046 2024-05-15 0001938046 us-gaap:ComputerEquipmentMember 2023-12-31 0001938046 us-gaap:ComputerEquipmentMember 2022-12-31 0001938046 us-gaap:EquipmentMember 2023-12-31 0001938046 us-gaap:EquipmentMember 2022-12-31 0001938046 MGRX:StockPurchaseAgreementMember 2021-12-09 2021-12-10 0001938046 MGRX:StockPurchaseAgreementMember 2022-03-17 2022-03-18 0001938046 MGRX:StockPurchaseAgreementMember 2023-01-01 2023-12-31 0001938046 MGRX:CohenEnterprisesIncMember 2022-06-15 2022-06-16 0001938046 MGRX:CohenEnterprisesIncMember 2022-06-16 0001938046 MGRX:StockPurchaseAgreementMember 2022-06-15 2022-06-16 0001938046 MGRX:CohenEnterprisesMember 2022-06-28 2022-06-29 0001938046 MGRX:CohenEnterprisesIncMember 2022-08-17 2022-08-18 0001938046 MGRX:CohenEnterprisesIncMember 2022-01-01 2022-12-31 0001938046 MGRX:CohenEnterprisesIncMember 2023-01-01 2023-12-31 0001938046 MGRX:ZipDoctorIncMember 2021-12-09 2021-12-10 0001938046 MGRX:ZipDoctorIncMember 2023-01-01 2023-12-31 0001938046 MGRX:ZipDoctorIncMember 2022-01-01 2022-12-31 0001938046 MGRX:StockPurchaseAgreementMember 2024-01-01 2024-06-30 0001938046 MGRX:CohenEnterprisesIncMember 2022-06-15 2022-06-16 0001938046 MGRX:ZipDoctorIncMember 2021-12-09 2021-12-10 0001938046 MGRX:CohenEnterprisesIncMember 2022-08-17 2022-08-18 0001938046 MGRX:CohenEnterprisesIncMember 2022-01-01 2022-12-31 0001938046 MGRX:CohenEnterprisesIncMember 2024-01-01 2024-06-30 0001938046 MGRX:CohenEnterprisesIncMember 2023-01-01 2023-12-31 0001938046 MGRX:RoninEquityPartnersMember 2024-03-01 0001938046 MGRX:CohenEnterprisesIncMember 2024-03-18 0001938046 MGRX:CohenEnterprisesIncMember 2024-04-01 0001938046 2022-11-18 0001938046 2023-01-01 2023-03-01 0001938046 2023-04-01 2023-04-01 0001938046 2023-03-23 2023-03-23 0001938046 us-gaap:RestrictedStockMember MGRX:DojoLabsMember 2023-01-03 2023-01-03 0001938046 us-gaap:RestrictedStockMember MGRX:DojoLabsMember 2023-01-03 0001938046 us-gaap:RestrictedStockMember MGRX:BethorLtdMember 2023-01-06 0001938046 us-gaap:RestrictedStockMember MGRX:BethorLtdMember 2023-01-06 2023-01-06 0001938046 MGRX:RudmanMember us-gaap:RestrictedStockMember 2023-01-06 2023-01-06 0001938046 MGRX:RudmanMember us-gaap:RestrictedStockMember 2023-01-06 0001938046 MGRX:BoonMember us-gaap:RestrictedStockMember 2023-01-06 2023-01-06 0001938046 MGRX:BoonMember us-gaap:RestrictedStockMember 2023-01-06 0001938046 MGRX:ConsultingAgreementsMember 2023-01-24 0001938046 MGRX:ConsultingAgreementsMember 2023-01-24 2023-01-24 0001938046 us-gaap:CommonStockMember 2023-03-22 2023-03-22 0001938046 us-gaap:CommonStockMember 2023-03-22 0001938046 MGRX:PrivatePlacementWarrantOneMember 2023-04-24 0001938046 MGRX:PrivatePlacementWarrantOneMember 2023-04-24 2023-04-24 0001938046 MGRX:PrivatePlacementWarrantTwoMember 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantTwoMember 2023-04-25 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantThreeMember 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantThreeMember 2023-04-25 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantFourMember 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantFourMember 2023-04-25 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantFiveMember 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantFiveMember 2023-04-25 2023-04-25 0001938046 MGRX:PrivatePlacementWarrantSixMember 2023-04-26 0001938046 MGRX:PrivatePlacementWarrantSixMember 2023-04-26 2023-04-26 0001938046 MGRX:PrivatePlacementWarrantSevenMember 2023-05-01 0001938046 MGRX:PrivatePlacementWarrantSevenMember 2023-05-01 2023-05-01 0001938046 MGRX:HammerMember 2023-05-01 2023-05-01 0001938046 MGRX:HammerMember 2023-05-01 0001938046 us-gaap:RestrictedStockMember MGRX:PrivatePlacementWarrantMember 2023-05-01 2023-05-01 0001938046 us-gaap:RestrictedStockMember MGRX:PrivatePlacementWarrantMember 2023-05-01 0001938046 MGRX:MrAndrewMember us-gaap:RestrictedStockMember MGRX:TwentyTwentyTwoPlanMember 2023-05-25 2023-05-25 0001938046 MGRX:MrAndrewMember us-gaap:RestrictedStockMember 2023-05-25 0001938046 MGRX:MrAndrewMember us-gaap:RestrictedStockMember 2023-05-25 2023-05-25 0001938046 MGRX:MajorDodgeMember us-gaap:RestrictedStockMember MGRX:TwentyTwentyTwoPlanMember 2023-06-01 2023-06-01 0001938046 MGRX:MajorDodgeMember us-gaap:RestrictedStockMember 2023-06-01 0001938046 MGRX:MajorDodgeMember us-gaap:RestrictedStockMember 2023-06-01 2023-06-01 0001938046 us-gaap:RestrictedStockMember MGRX:StreetGroupLLCMember 2023-06-01 2023-06-01 0001938046 us-gaap:RestrictedStockMember MGRX:StreetGroupLLCMember 2023-06-01 0001938046 MGRX:PrivatePlacementWarrantMember 2023-06-05 0001938046 MGRX:PrivatePlacementWarrantMember 2023-06-05 2023-06-05 0001938046 MGRX:PrivatePlacementWarrantOneMember 2023-06-06 0001938046 MGRX:PrivatePlacementWarrantOneMember 2023-06-06 2023-06-06 0001938046 MGRX:PrivatePlacementWarrantTwoMember 2023-06-07 0001938046 MGRX:PrivatePlacementWarrantTwoMember 2023-06-07 2023-06-07 0001938046 MGRX:PrivatePlacementWarrantThreeMember 2023-06-08 0001938046 MGRX:PrivatePlacementWarrantThreeMember 2023-06-08 2023-06-08 0001938046 MGRX:PrivatePlacementWarrantFourMember 2023-06-21 0001938046 MGRX:PrivatePlacementWarrantFourMember 2023-06-21 2023-06-21 0001938046 MGRX:PrivatePlacementWarrantFiveMember 2023-06-22 0001938046 MGRX:PrivatePlacementWarrantFiveMember 2023-06-22 2023-06-22 0001938046 MGRX:PrivatePlacementWarrantSixMember 2023-06-27 0001938046 MGRX:PrivatePlacementWarrantSixMember 2023-06-27 2023-06-27 0001938046 us-gaap:RestrictedStockMember MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2023-01-01 2023-12-31 0001938046 MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2023-12-31 0001938046 MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2023-01-01 2023-12-31 0001938046 MGRX:ConsultingAgreementMember 2023-10-01 2023-10-01 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2023-10-10 2023-10-10 0001938046 MGRX:LucaConsultingLlcMember 2023-10-10 2023-10-10 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2023-10-10 0001938046 us-gaap:RestrictedStockMember MGRX:JasonSzkupMember 2023-11-01 2023-11-01 0001938046 us-gaap:RestrictedStockMember MGRX:JasonSzkupMember 2023-11-01 0001938046 MGRX:DrDouglasChristiansonMember us-gaap:RestrictedStockMember 2023-11-01 2023-11-01 0001938046 MGRX:MrAndrewMember us-gaap:RestrictedStockMember 2023-11-01 0001938046 us-gaap:RestrictedStockMember MGRX:PHXGlobalLLCMember 2023-11-15 2023-11-15 0001938046 us-gaap:RestrictedStockMember MGRX:PHXGlobalLLCMember 2023-11-15 0001938046 MGRX:MariusPharmaceuticalsMember us-gaap:RestrictedStockMember 2023-12-11 2023-12-11 0001938046 us-gaap:RestrictedStockMember MGRX:MariusPharmaceuticalsMember 2023-12-11 0001938046 us-gaap:RestrictedStockMember MGRX:MariusPharmaceuticalsMember 2023-12-11 2023-12-11 0001938046 us-gaap:CommonStockMember 2023-12-19 0001938046 MGRX:TwentyTwentyTwoPlanMember us-gaap:CommonStockMember 2022-12-31 0001938046 srt:ChiefExecutiveOfficerMember MGRX:TwentyTwentyTwoPlanMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001938046 srt:ChiefOperatingOfficerMember MGRX:TwentyTwentyTwoPlanMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001938046 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2022-12-31 0001938046 MGRX:TwentyTwentyTwoPlanMember us-gaap:CommonStockMember 2023-05-01 0001938046 us-gaap:CommonStockMember 2023-05-01 0001938046 us-gaap:CommonStockMember 2023-05-01 2023-05-01 0001938046 MGRX:TwentyTwentyTwoPlanMember us-gaap:CommonStockMember 2023-12-28 0001938046 us-gaap:CommonStockMember 2023-12-28 0001938046 us-gaap:CommonStockMember 2023-12-28 2023-12-28 0001938046 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001938046 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-03-20 0001938046 2023-03-20 2023-03-20 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-12-19 0001938046 us-gaap:WarrantMember 2023-12-19 2023-12-19 0001938046 us-gaap:InvestorMember 2023-12-31 0001938046 us-gaap:InvestorMember 2022-12-31 0001938046 MGRX:SeriesBConvertiblePreferredStockMember 2024-03-28 0001938046 MGRX:WarrantTwoMember MGRX:UnderwritingAgreementMember 2024-06-28 0001938046 us-gaap:SeriesBPreferredStockMember 2024-05-21 2024-05-21 0001938046 us-gaap:SeriesBPreferredStockMember 2024-05-22 2024-05-22 0001938046 us-gaap:SeriesBPreferredStockMember 2024-05-24 2024-05-24 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2024-04-18 2024-04-18 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2024-04-18 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2024-06-30 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember 2023-12-31 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 2024-04-24 0001938046 MGRX:SixPercentageSeriesCConvertibleCumulativePreferredStockMember MGRX:IPPurchaseAgreementMember 2024-04-24 0001938046 us-gaap:RestrictedStockMember 2023-01-24 2023-01-24 0001938046 MGRX:MrAndrewMember us-gaap:RestrictedStockMember MGRX:TwentyTwentyTwoPlanMember 2023-05-25 0001938046 MGRX:MajorDodgeMember us-gaap:RestrictedStockMember MGRX:TwentyTwentyTwoPlanMember 2023-06-01 0001938046 us-gaap:RestrictedStockMember MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2024-01-01 2024-06-30 0001938046 MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2024-06-30 0001938046 MGRX:ServiceAgreementMember MGRX:GreentreeFinancialGroupMember 2024-01-01 2024-06-30 0001938046 MGRX:DrDouglasChristiansonMember us-gaap:RestrictedStockMember 2023-11-01 0001938046 MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-01-02 2024-01-02 0001938046 MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-01-02 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-01-10 2024-01-10 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-01-10 0001938046 MGRX:ConsultingAgreementMember MGRX:FirstLevelCapitalMember 2024-01-11 2024-01-11 0001938046 MGRX:ConsultingAgreementMember MGRX:FirstLevelCapitalMember 2024-01-11 0001938046 MGRX:TwentyTwentyTwoEquityIncentivePlanMember MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-02-07 2024-02-07 0001938046 MGRX:TwentyTwentyTwoEquityIncentivePlanMember MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-02-07 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-03-21 2024-03-21 0001938046 MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-03-21 0001938046 MGRX:ConsultingAgreementMember MGRX:ZvonimirMoricConsultingMember 2024-03-21 2024-03-21 0001938046 MGRX:ConsultingAgreementMember MGRX:ZvonimirMoricConsultingMember 2024-03-21 0001938046 MGRX:EquityPurchaseAgreementMember 2024-04-08 2024-04-08 0001938046 MGRX:CommitmentSharesMember MGRX:EquityPurchaseAgreementMember 2024-04-08 0001938046 MGRX:CommitmentSharesMember MGRX:EquityPurchaseAgreementMember 2024-04-08 2024-04-08 0001938046 us-gaap:RestrictedStockMember MGRX:PHXGlobalLLCMember 2024-04-25 2024-04-25 0001938046 MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember MGRX:PHXGlobalLLCMember 2024-04-25 2024-04-25 0001938046 MGRX:TwoThousandTwentyTwoEquityIncentivePlanMember MGRX:PHXGlobalLLCMember 2024-04-25 0001938046 us-gaap:SeriesBPreferredStockMember 2024-05-21 2024-05-24 0001938046 us-gaap:SeriesBPreferredStockMember 2024-05-24 0001938046 MGRX:EquityPurchaseAgreementMember 2024-05-21 2024-05-21 0001938046 MGRX:EquityPurchaseAgreementMember 2024-05-21 0001938046 MGRX:EquityPurchaseAgreementMember 2024-05-22 2024-05-22 0001938046 MGRX:EquityPurchaseAgreementMember 2024-05-22 0001938046 MGRX:ConsultingAgreementMember MGRX:AcornManagementPartnersLLCMember 2024-05-23 2024-05-23 0001938046 MGRX:ConsultingAgreementMember MGRX:AcornManagementPartnersLLCMember 2024-05-23 0001938046 MGRX:OfficersDirectorsAndEmployeesMember 2024-06-05 2024-06-05 0001938046 MGRX:ChiefExecutiveOfficerAndChairmanMember 2024-06-05 2024-06-05 0001938046 srt:ChiefOperatingOfficerMember 2024-06-05 2024-06-05 0001938046 srt:PresidentMember 2024-06-05 2024-06-05 0001938046 MGRX:ThreeIndependentDirectorsMember 2024-06-05 2024-06-05 0001938046 MGRX:TwentyTwentyTwoEquityIncentivePlanMember 2024-06-05 0001938046 MGRX:TwentyTwentyTwoEquityIncentivePlanMember 2024-06-05 2024-06-05 0001938046 2024-03-28 0001938046 2024-06-28 0001938046 MGRX:PrivatePlacementWarrantMember 2022-08-31 0001938046 MGRX:TwentyThreeAccreditedInvestorsMember MGRX:PrivatePlacementWarrantMember 2022-08-16 2022-12-22 0001938046 MGRX:TwentyThreeAccreditedInvestorsMember MGRX:PrivatePlacementWarrantMember 2022-08-16 2022-12-12 0001938046 MGRX:PrivatePlacementWarrantMember 2024-06-30 0001938046 MGRX:PrivatePlacementWarrantMember 2023-12-31 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-03-20 2023-03-20 0001938046 us-gaap:CommonStockMember us-gaap:IPOMember 2023-12-19 2023-12-19 0001938046 us-gaap:WarrantMember MGRX:UnderwritingAgreementMember 2024-01-22 0001938046 MGRX:UnderwritingAgreementMember 2024-01-22 2024-01-22 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-04 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-04-04 2024-04-04 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 2024-06-28 0001938046 us-gaap:WarrantMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 0001938046 MGRX:WarrantOneMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 2024-06-28 0001938046 MGRX:WarrantOneMember MGRX:SecuritiesPurchaseAgreementMember 2024-06-28 0001938046 us-gaap:InvestorMember 2024-06-30 0001938046 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001938046 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001938046 MGRX:RangeOneMember 2023-12-31 0001938046 MGRX:RangeOneMember 2023-01-01 2023-12-31 0001938046 MGRX:RangeTwoMember 2023-12-31 0001938046 MGRX:RangeTwoMember 2023-01-01 2023-12-31 0001938046 srt:MaximumMember 2023-01-01 2023-12-31 0001938046 srt:MinimumMember 2023-01-01 2023-12-31 0001938046 srt:MinimumMember us-gaap:WarrantMember 2023-12-31 0001938046 srt:MaximumMember us-gaap:WarrantMember 2023-12-31 0001938046 srt:MinimumMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001938046 srt:MaximumMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001938046 2022-09-28 0001938046 2022-09-28 2022-09-28 0001938046 MGRX:LeaseAgreementMember 2022-09-28 2022-09-28 0001938046 srt:MaximumMember 2017-12-22 2017-12-22 0001938046 srt:MinimumMember 2017-12-22 2017-12-22 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-01-02 2024-01-02 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:GAndPGeneralConsultingMember 2024-01-02 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-01-10 2024-01-10 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-01-10 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:FirstLevelCapitalMember 2024-01-11 2024-01-11 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:FirstLevelCapitalMember 2024-01-11 0001938046 MGRX:UnderwritersMember us-gaap:SubsequentEventMember 2024-01-18 2024-01-18 0001938046 MGRX:UnderwritersMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-01-18 2024-01-18 0001938046 us-gaap:WarrantMember us-gaap:SubsequentEventMember MGRX:UnderwritingAgreementMember 2024-01-22 0001938046 us-gaap:SubsequentEventMember MGRX:UnderwritingAgreementMember 2024-01-22 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-03-21 2024-03-21 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:LucaConsultingLlcMember 2024-03-21 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:ZvonimirMoricConsultingMember 2024-03-21 2024-03-21 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember MGRX:ZvonimirMoricConsultingMember 2024-03-21 0001938046 us-gaap:SubsequentEventMember MGRX:RoninEquityPartnersMember 2024-04-01 0001938046 us-gaap:SubsequentEventMember MGRX:CohenEnterprisesIncMember 2024-03-18 0001938046 MGRX:TwoThouandTwentyTwoPlanMember us-gaap:SubsequentEventMember 2024-03-25 2024-03-25 0001938046 MGRX:TwoThouandTwentyTwoPlanMember us-gaap:SubsequentEventMember 2024-03-25 0001938046 MGRX:TwoThouandTwentyTwoPlanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-25 0001938046 MGRX:TwoThouandTwentyTwoPlanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-25 2024-03-25 0001938046 us-gaap:SubsequentEventMember 2024-03-25 0001938046 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-07-08 2024-07-08 0001938046 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-07-08 0001938046 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-07-25 2024-07-25 0001938046 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-07-25 0001938046 MGRX:JohnDorseyMember us-gaap:SubsequentEventMember MGRX:ConsultingAgreementMember 2024-07-30 2024-07-30 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementsMember 2024-07-30 0001938046 us-gaap:SubsequentEventMember MGRX:ConsultingAgreementsMember 2024-07-30 2024-07-30 0001938046 MGRX:InitialClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:InitialClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:SecondClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:SecondClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:ThirdClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:ThirdClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:FourthClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:FourthClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:InitialClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:InitialClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:SecondClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:SecondClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:ThirdClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:ThirdClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:FourthClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:FourthClosingMember MGRX:SharePurchaseAgreementMember 2024-04-28 2024-04-28 0001938046 MGRX:PurchaserMember MGRX:SharePurchaseAgreementMember 2024-04-28 0001938046 MGRX:PeriodEndSpotRateMember 2024-06-30 0001938046 country:MX MGRX:PeriodEndSpotRateMember 2024-06-30 0001938046 MGRX:AverageRateMember 2024-06-30 0001938046 country:MX MGRX:AverageRateMember 2024-06-30 0001938046 MGRX:RangeOneMember 2024-06-30 0001938046 MGRX:RangeOneMember 2024-01-01 2024-06-30 0001938046 MGRX:RangeTwoMember 2024-06-30 0001938046 MGRX:RangeTwoMember 2024-01-01 2024-06-30 0001938046 srt:MaximumMember 2024-01-01 2024-06-30 0001938046 srt:MinimumMember 2024-01-01 2024-06-30 0001938046 srt:MinimumMember us-gaap:WarrantMember 2024-06-30 0001938046 srt:MaximumMember us-gaap:WarrantMember 2024-06-30 0001938046 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001938046 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-06-30 iso4217:USD shares iso4217:USD shares utr:sqft pure false 0001938046 S-1 Mangoceuticals, Inc. TX 8099 87-3841292 15110 N. Dallas Parkway Suite 600 Dallas TX 75248 (214) 242-9619 Jacob D. Cohen 15110 N. Dallas Parkway Suite 600 Dallas TX 75248 (214) 242-9619 Non-accelerated Filer true true false 739006 682860 18501 60953 11745 818460 694605 28752 3863 96129 117499 96129 117499 16942 16942 119262 174241 136204 191183 136204 191183 1050793 1003287 140765 33675 6595 2717 89200 78260 63718 56725 211078 260577 64961 128680 64961 128680 276039 389257 0.0001 0.0001 200000000 200000000 21419500 21419500 13365000 13365000 2142 1337 12000785 2628449 -11228173 -2015756 774754 614030 774754 614030 1050793 1003287 731493 8939 154900 4089 145092 431501 4850 3319417 1643572 977890 2097505 352860 1100465 2155114 9650391 1996432 -9218890 -1991582 6473 -6473 6473 -6473 -9212417 -1998055 -9212417 -1998055 -9212417 -1998055 -0.57 -0.57 -0.19 -0.19 16113029 16113029 10798083 10798083 8000000 800 181 -17701 -16720 3365000 337 539728 540065 2000000 200 1999800 2000000 234088 234088 151821 151821 6473 6473 -1998055 -1998055 13365000 1337 2628449 -2015756 614030 13365000 1337 2628449 -2015756 614030 1780000 178 1530473 1530651 5250000 525 6199475 6200000 -6473 -6473 624463 624463 1024500 102 1024398 1024500 -9212417 -9212417 21419500 2142 12000785 -11228173 774754 21419500 2142 12000785 -11228173 774754 -9212417 -1998055 24889 3863 1530651 540065 6473 -6473 624463 234088 -151821 16942 18501 49208 11745 -54979 174241 107090 33675 -56726 185405 3878 2717 -6997375 -1346518 3519 43102 -3519 -43102 75000 78260 89200 25070 1024500 6200000 2000000 7057040 2049930 56146 660310 682860 22550 739006 682860 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z48SHvmP06qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_823_zZuHNSWJ50fb">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. (“Mangoceuticals” or the “Company”), was incorporated in the State of a Texas on October 7, 2021, with the intent of focusing on developing, marketing, and selling a variety of men’s wellness products and services via a telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (“ED”), hair loss and testosterone replacement or enhancement therapies. In this regard, Mangoceuticals has developed and is commercially marketing a new brand of ED products under the brand name “Mango” and a new brand of hair loss products under the brand name “Grow.” These products are produced at a compounding pharmacy using a proprietary combination of U.S. Food and Drug Administration (“FDA”) approved ingredients and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling these branded ED and hair loss products exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Public Offering. </i>In March 2023, the Company completed an initial public offering (the “IPO”), in which the Company issued and sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGSfjDOxjYeh" title="Issuance of shares">1,250,000</span> shares of authorized common stock for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zB37AutQC6o4" title="Share issued price per share">4.00</span> per share for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zA6iUJDRycTd" title="Net proceeds from issuance of common stock">4.35</span> million, after deducting underwriting discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate prospectus (the “Resale Prospectus”) the Company registered the sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zEONUtNhJ9f" title="Sale of stock, shares">4,765,000</span> shares of common stock, including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_z7uUHvOdMAvi" title="Issuance of shares">2,000,000</span> shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zXQzlnZtWo44" title="Share issued price per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1250000 4.00 4350000 4765000 2000000 1.00 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_ztN4wXi31Ow" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82A_z84VqzX3SS05">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zboBSjx0Odpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ztmBDmoHdr1a">Basis of Presentation</span> – </b>The financial statements present the financial position, results of operations and cash flows of the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). All dollar amounts are rounded to the nearest thousand dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZVyE6Q2xFJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zcEFdB4ZWIM2">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zMUPb0C0wYSl" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zDkNsjqsn9F5" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zYPyKRbZiDre" title="Cash equivalents">no</span></span> cash equivalents at December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zSB5lcPjmO3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zniKsZWDzY76">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, <i>Income Taxes</i>. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z3jq9bm6w6Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zSWqOfnQBtmf">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zl0jxlh92BL7" title="Anti-dilutive securities">2,650,000</span> options, <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsGfzbl0XRI" title="Anti-dilutive securities">1,343,000</span> warrants and no derivative securities outstanding as of December 31, 2023. There were <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zAlRNhoTR6Ui" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6ZAroPv8EQk" title="Anti-dilutive securities">2,000,000</span> warrants and no derivative securities outstanding as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zTaBj30XFrTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zamGauzDKjhd">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zaM9Hxx303Ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z11SItixPdGg">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, <i>Fair Value Measurement</i> (“ASC 820”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize our financial instruments measured at fair value as of December 31, 2023 and 2022.</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmCwPWoDEy48" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_z76vasqmTcJh" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM4HMvah6b5f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjN7dNJOHvoh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1RGznAsYY0e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zKeMzD4xyxnl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzlJz_maFVNALzvC8_zJk1zAIb3nv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">739,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zvbRTr91lye" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzvC8_zm6eNibZcf16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z88h79UYA6l3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzT2Nreep0Ii" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zif1Ktf5CoC3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzx9H_zYHNmXtfARC" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzx9H_maFVNALzcay_zBk6Oom2ma0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">682,860</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzcay_zUNjE5BQuN3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzcay_zU4WNRYuL3uj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z5kiy43EGDxk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zwhsJcxJ8kA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z9VfdyLyUJqg">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zfntVJl5UiHk" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zmM4uTqaHtl" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zYXIXKxlUq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDtTJX7Zm2Ol">Concentration and Risks</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2023 and 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOZSMwBGjNbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zyOY2JANQlti">Black-Scholes Option Pricing Model</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTXglG99Xpx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zKByrpyXS966">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, <i><span style="text-decoration: underline">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) </span></i>(“<span style="text-decoration: underline">ASU 2020-06</span>”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in US GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--RelatedPartiesPolicyTextBlock_zxSMW5Skww2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zuF8qaZSuBVb">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuDxx74dHn83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z9nY045imVwh">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVhTNJGZONoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zYUvfVw9H8g9">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 606. <i>Revenue from Contracts with Customer for recording and recognizing revenue from customers</i>. The Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_z2G8dZgf39hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zTsiJf1OADed">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the years ended December 31, 2023 and 2022, there were <span id="xdx_90A_eus-gaap--InventoryWriteDown_do_c20230101__20231231_z9SdocJ1w2m7" title="Inventory write down"><span id="xdx_90A_eus-gaap--InventoryWriteDown_do_c20220101__20221231_zQrcxh2fYr43" title="Inventory write down">no</span></span> inventory write-downs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_z4aAnGiVRdTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zcKz29pmo7s5">Marketing and Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_zYPBOjllJ9v2" title="Marketing and advertising expense">2,097,505</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20221231_zx6CFkxa8gIe" title="Marketing and advertising expense">352,860</span> towards marketing and advertising for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zCX8wMDdbJHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zFVwvXar9EQi">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in Section 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 12).</span></p> <p id="xdx_851_zNqt8wSzQYje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zboBSjx0Odpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ztmBDmoHdr1a">Basis of Presentation</span> – </b>The financial statements present the financial position, results of operations and cash flows of the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). All dollar amounts are rounded to the nearest thousand dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zZVyE6Q2xFJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zcEFdB4ZWIM2">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“FDIC”) insures the total cash balance up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zMUPb0C0wYSl" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zDkNsjqsn9F5" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zYPyKRbZiDre" title="Cash equivalents">no</span></span> cash equivalents at December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 0 0 <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zSB5lcPjmO3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zniKsZWDzY76">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are provided in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, <i>Income Taxes</i>. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z3jq9bm6w6Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zSWqOfnQBtmf">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zl0jxlh92BL7" title="Anti-dilutive securities">2,650,000</span> options, <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsGfzbl0XRI" title="Anti-dilutive securities">1,343,000</span> warrants and no derivative securities outstanding as of December 31, 2023. There were <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zAlRNhoTR6Ui" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6ZAroPv8EQk" title="Anti-dilutive securities">2,000,000</span> warrants and no derivative securities outstanding as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2650000 1343000 1250000 2000000 <p id="xdx_844_eus-gaap--UseOfEstimates_zTaBj30XFrTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zamGauzDKjhd">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zaM9Hxx303Ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z11SItixPdGg">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, <i>Fair Value Measurement</i> (“ASC 820”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize our financial instruments measured at fair value as of December 31, 2023 and 2022.</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmCwPWoDEy48" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_z76vasqmTcJh" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM4HMvah6b5f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjN7dNJOHvoh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1RGznAsYY0e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zKeMzD4xyxnl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzlJz_maFVNALzvC8_zJk1zAIb3nv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">739,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zvbRTr91lye" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzvC8_zm6eNibZcf16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z88h79UYA6l3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzT2Nreep0Ii" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zif1Ktf5CoC3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzx9H_zYHNmXtfARC" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzx9H_maFVNALzcay_zBk6Oom2ma0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">682,860</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzcay_zUNjE5BQuN3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzcay_zU4WNRYuL3uj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z5kiy43EGDxk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmCwPWoDEy48" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_z76vasqmTcJh" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM4HMvah6b5f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjN7dNJOHvoh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1RGznAsYY0e" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zKeMzD4xyxnl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzlJz_maFVNALzvC8_zJk1zAIb3nv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">739,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zvbRTr91lye" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzvC8_zm6eNibZcf16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z88h79UYA6l3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zzT2Nreep0Ii" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zif1Ktf5CoC3" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzx9H_zYHNmXtfARC" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AssetsFairValueDisclosure_iI_mtAFVDzx9H_maFVNALzcay_zBk6Oom2ma0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">682,860</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzcay_zUNjE5BQuN3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_mtFVNALzcay_zU4WNRYuL3uj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 739006 739006 739006 682860 682860 682860 <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zwhsJcxJ8kA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z9VfdyLyUJqg">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zfntVJl5UiHk" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zmM4uTqaHtl" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P5Y <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zYXIXKxlUq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDtTJX7Zm2Ol">Concentration and Risks</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2023 and 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOZSMwBGjNbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zyOY2JANQlti">Black-Scholes Option Pricing Model</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTXglG99Xpx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zKByrpyXS966">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, <i><span style="text-decoration: underline">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) </span></i>(“<span style="text-decoration: underline">ASU 2020-06</span>”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in US GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--RelatedPartiesPolicyTextBlock_zxSMW5Skww2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zuF8qaZSuBVb">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuDxx74dHn83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z9nY045imVwh">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (“ASC 718”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zVhTNJGZONoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zYUvfVw9H8g9">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 606. <i>Revenue from Contracts with Customer for recording and recognizing revenue from customers</i>. The Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“Doctegrity”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“Contracted Pharmacy”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_z2G8dZgf39hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zTsiJf1OADed">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“FIFO”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the years ended December 31, 2023 and 2022, there were <span id="xdx_90A_eus-gaap--InventoryWriteDown_do_c20230101__20231231_z9SdocJ1w2m7" title="Inventory write down"><span id="xdx_90A_eus-gaap--InventoryWriteDown_do_c20220101__20221231_zQrcxh2fYr43" title="Inventory write down">no</span></span> inventory write-downs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_z4aAnGiVRdTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zcKz29pmo7s5">Marketing and Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $<span id="xdx_908_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20231231_zYPBOjllJ9v2" title="Marketing and advertising expense">2,097,505</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20221231_zx6CFkxa8gIe" title="Marketing and advertising expense">352,860</span> towards marketing and advertising for the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2097505 352860 <p id="xdx_84A_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zCX8wMDdbJHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zFVwvXar9EQi">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in Section 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 12).</span></p> <p id="xdx_80C_ecustom--PrepaidExpensesRelatedPartiesTextBlock_zsC7tkCBOBjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_822_zmhCJDk8ffY2">PREPAID EXPENSES-RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy as a retainer to be credited towards future product sales. As of December 31, 2023 and 2022, the balance was $<span id="xdx_909_ecustom--PrepaidExpensesRelatedParty_iI_c20231231_zO9zjRvRy3Qc" title="Prepaid expenses related party">60,953</span> and $<span id="xdx_904_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_zjaHHCXSygik" title="Prepaid expenses related party">11,745</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $<span id="xdx_90A_eus-gaap--Deposits_iI_c20221001_zLMEL1qgBdrc" title="Security deposits">16,942</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 60953 11745 16942 <p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zVDOeMFthYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_829_zB1MeBLyOXv3">INVENTORY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023 and 2022, the Company purchased inventories related to promotional merchandise intended to be sold online. As of December 31, 2023 and 2022, the inventory balance was $<span id="xdx_901_eus-gaap--InventoryNet_iI_c20231231_z7AyAj17lIhk" title="Inventory">18,501</span> and $<span id="xdx_902_eus-gaap--InventoryNet_iI_dxL_c20221231_zBYjpBRuhWQ1" title="Inventory::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0912">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 18501 <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNLqKxU9KBfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82A_zOIrqr9pmew2">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company acquired computers and office equipment totaling $3,519. Depreciation for the year ended December 31, 2023 and 2022 was $<span id="xdx_903_eus-gaap--Depreciation_c20230101__20231231_zE4Z6eciGZK3" title="Depreciation expense">24,889</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20220101__20221231_zxJj6H9kxrhg" title="Depreciation expense">3,863</span>, respectively. Total net property, plant and equipment was $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zwQCEv4Jexl5" title="Property plant and equipment net">96,129</span> and $<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zefA9TRNYVh3" title="Property plant and equipment net">117,499</span>, as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_ztNGuZVaZOXc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z2oC8ANaN1N1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_ziiJIyDu4Wp2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zNLOheRmGeY6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zeaizQL2JeC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 52%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zm44MhtjFtTf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,819</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNUP9a8iZRRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation:</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,752</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z6MXR5PyzwE3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">96,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zvzctRbv1cgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 24889 3863 96129 117499 <p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_ztNGuZVaZOXc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z2oC8ANaN1N1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20231231_ziiJIyDu4Wp2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zNLOheRmGeY6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zeaizQL2JeC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 52%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zm44MhtjFtTf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,819</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNUP9a8iZRRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation:</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,752</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z6MXR5PyzwE3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">96,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5062 5062 119819 116300 28752 3863 96129 117499 <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zbsOXKeUq6A6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_821_zLCGfAsD9Xi8">LOANS FROM RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211209__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zPO1PdB62Dvh" title="Related party advances received">39,200</span> and $<span id="xdx_900_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220317__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z3Q8NRIKMuE1" title="Related party advances received">50,000</span>, respectively, for a total of $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zKyU6X5zaPxj" title="Related party advances received">89,200</span> from its previous majority shareholder, American International Holdings Corp (“AMIH”), in order to cover various general and administrative expenses. The advances bear no interest and are due on demand upon the Company’s ability to repay the advances from either future revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (“Cohen Enterprises”), an entity owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman of the Board of Directors, entered into and closed a Stock Purchase Agreement (the “SPA”) for the purchase of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zN72iczFQLof" title="Issuance of shares">8,000,000</span> shares of the outstanding common stock of the Company which were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zSZz3VtVeNcg" title="Equity ownership interest">80</span>% of the Company’s then outstanding shares of common stock, in consideration for $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zIjwPnqDfyg7" title="Proceeds from issuance of common stock">90,000</span>. Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zAikz02gTSrd" title="Repayments of related party debt">89,200</span> advanced from AMIH to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2022, the Company received an advance of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__srt--TitleOfIndividualAxis__custom--CohenEnterprisesMember_zmCVvBHNCGE7" title="Related party advances received">25,000</span> from Cohen Enterprises in order to cover various general and administrative expenses. The Company repaid Cohen Enterprises $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zppdmBSkzWnb" title="Repayments of related party debt">25,000</span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zG2h17FSbP9f" title="Repayment of related party debt">89,200</span> as of December 31, 2022. This amount was paid in full on April 4, 2023 and the amount owed to Cohen Enterprises was $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zTfFHcF24D6l" title="Proceeds from related party">0</span> and $<span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zX0Bk6ahAY3f" title="Proceeds from related party">89,200</span> as of December 31, 2023 and 2022, respectively. Previously recorded imputed interest equal to eight percent (<span id="xdx_907_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zduhkC0EcCV1" title="Imputed interest percentage">8</span>%) per annum, or a total of $<span id="xdx_907_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zSGHJc3F3Dte" title="Related party transaction purchases">8,232</span> against the related party advances, was canceled and reversed for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 10, 2021, the Company received an advance of $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211209__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zK7gmUVruBlk" title="Related party advances received">70</span> from ZipDoctor, Inc., a then wholly-owned subsidiary of its then majority shareholder, AMIH, which was used to open and establish the Company’s bank account. The advance bears no interest and is due on demand upon the Company’s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May 24, 2022 and the amount owed to ZipDoctor was $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zzJvTbwP7Z2a" title="Repayment of debt">0</span> and $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zLVXFQHUeVdg" title="Repayment of debt">70</span> as of December 31, 2023 and 2022, respectively. Imputed interest at eight percent (<span id="xdx_90F_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zBCRR28XGzYd" title="Imputed interest percentage">8</span>%) per annum on this advance was insignificant and therefore was not calculated, recorded or paid during the time the advance was outstanding from December 10, 2021 to May 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For additional information on related party prepaid expenses see Note 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 39200 50000 89200 8000000 0.80 90000 89200 25000 25000 89200 0 89200 0.08 8232 70 0 70 0.08 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zrJMx6pRacN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_826_z9QOGB4jEzXc">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_zCMTJgbBg0X" title="Debt instrument face amount">78,260</span>. The note bears no interest and was due in three payments of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230301_zrxzULb2FmZ7" title="Debt instrument periodic payment">5,000</span> each January 1, 2023 through March 1, 2023, a $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_zj9JXT0oJUk1" title="Debt instrument periodic payment">31,630</span> payment on April 1, 2023 and a final payment on May 1, 2023 for the outstanding balance. The January 1 and March 1, 2023 payments were timely made and on March 23, 2023, the Company elected to pay off the remaining balance of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20230323__20230323_zHWzYzr4L1H9" title="Repayments of notes payable">63,260</span>. The outstanding balance as of December 31, 2023 and 2022 was $<span id="xdx_905_eus-gaap--NotesPayable_iI_dxL_c20231231_zIKYTrBYSXJh" title="Notes payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0986">0</span></span> and <span id="xdx_904_eus-gaap--NotesPayable_iI_dxL_c20221231_zljDGlu01b3d" title="Notes payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0988">78,260</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 78260 5000 31630 63260 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrE4dSBt9UXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_827_zhYvydESBjb8">CAPITAL STOCK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue up to <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_z3LlrpKMUpKe" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zQYaqDk0FyRd" title="Preferred stock, shares authorized">10,000,000</span></span> shares of “blank check” preferred stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20231231_zhJsikQngaM4" title="Preferred stock par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zBB4IfmoPuAl" title="Preferred stock par value">0.0001</span></span> par value. All preferred stock were undesignated as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zgypt4CsEzre" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zoqevXfQSal7" title="Common stock, shares authorized">200,000,000</span></span> shares of common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20231231_z6zC2fsqG6g1" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zpqXIHxyOeI5" title="Common stock, par value">0.0001</span></span> per share, of which <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20231231_zfDrVuFD3P08" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z0qHt683whv4" title="Common stock shares, outstanding">21,419,500</span></span> shares were issued and outstanding at December 31, 2023 and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20221231_zhv6qUKsuGQ6" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zB7isOXk37Mi" title="Common stock, shares outstanding">13,365,000</span></span> were issued and outstanding at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“DojoLabs”), to provide various strategic marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXLDAppfBcjh" title="Shares issued">100,000</span> in cash and issued DojoLabs <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5esJVVOsWU1" title="Shares issued">50,000</span> shares of restricted common stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zy8w539jPDYl" title="Share price">1.00</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcSvRgfPTTEd" title="Shares issued value">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“Bethor”), to provide strategic advisory services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Bethor 250,000 shares of restricted common stock with registration rights. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zM7zP15yYHH3" title="Share price">1.00</span> per share for a total of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zo3u4QKpwWp" title="Shares issued value">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, the Company established an advisory board (the “Advisory Board”) and approved and adopted a charter (the “Advisory Board Charter”) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“Dr. Rudman”) and Mr. Jarrett Boon (“Mr. Boon”), both of whom are independent, non-Board members and non-Company employees, to the Advisory Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Rudman Consulting Agreement”), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLUvxCo7kgNf" title="Shares issued">25,000</span> shares of the Company’s restricted common stock, pay Dr. Rudman $<span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4rpW9KRkfk" title="Compensation expense">2,000</span> per month in cash, and reimburse Dr. Rudman for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0PzKxsbFjY1" title="Share price">1.00</span> per share for a total of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBY6eZViltxl" title="Shares issued value">25,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Boon Consulting Agreement”), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxHKhLkeo75c" title="Shares issued">25,000</span> shares of the Company’s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znpEicKFUAN5" title="Share price">1.00</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuVQD3nILvzc" title="Shares issued value">25,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. Any shares not vested by the eighteen-month anniversary of the applicable agreement are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_z2JGa3LGf22d" title="Share price">1.00</span> per share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zFwDzm22lU9j" title="Shares issued value">350,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2023, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAacI7BOTj5k" title="Number of shares sold">1,250,000</span> shares of its common stock at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPcUMQwp5yF" title="Share price">4.00</span> per share to investors in connection with its IPO for gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWOn3ZiQuvna" title="Gross proceeds">5,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 24, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zjajtZ03aQrd" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z12UCKTdmXl1" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230424__20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z6jIk7CKmw7" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zblNMOuBpLYf" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zcOUxgcOcqph" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z8TYqsjtIVV6" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zpTJYw4UTlB1" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zZuQoht9Alm9" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zuPRxd6apGvi" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_z701Kv3QIKxk" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zk6rMwvNdbl8" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zj1Rtllpfy1" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_z6OLEMMeni67" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zL02Ac8hMRsb" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zArOH2iAZiAi" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zWu49prRdhG3" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_z4j6RXt84GUj" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230426__20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zrY7LFs9k8K2" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zFLY9j8SpZe6" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zUyRDc8VpfE7" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_znCNGrwu5h2d" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the “Employment Agreement”). The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for Mrs. Hammer to receive an annual salary of $<span id="xdx_906_eus-gaap--PaymentsToEmployees_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zxS9dkYe4pK3" title="Annual salary">150,000</span> per year. The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_uUSDPShares_c20230501__srt--TitleOfIndividualAxis__custom--HammerMember_za8wAArJseNc" title="Exercise price">1.00</span> per share, with options to purchase <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_z7eNpx0puyy2" title="Shares vesting">50,000</span> shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and Mrs. Hammer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (“Redlime”) to provide software development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Redlime $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFC7PcoRQ4a8" title="Consideration paid">300,000</span> in cash and issue Redlime <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXN317aNKZr1" title="Shares new issues">180,000</span> shares of restricted common stock. The shares were valued at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHLazLVKqLKi" title="Share price">1.00</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBdJip571t7g" title="Shares issued value">180,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (“Mr. Andrew”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Mr. Andrew’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Mr. Andrew Consulting Agreement”), dated effective May 25, 2023, with Mr. Andrew, whereby the Company agreed to issue Mr. Andrew <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z4xfYuJ1sRG" title="Shares issued">50,000</span> shares of the Company’s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIGGDyesSek6" title="Share price">1.10</span> per share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyv7CcvBaVL4" title="Shares issued value">55,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2023, we entered into a Consulting Agreement with Major Dodge (“Major”), to provide acting and production related services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Major <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zbsJGhFoOeU6" title="Shares issued">20,000</span> shares of restricted common stock under the 2022 Plan. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeYwZ8sIZIzi" title="Share price">1.10</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoRzu1SOTvC5" title="Shares issued value">22,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (“New To The Street”), to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which is for 3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company issued New To The Street <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2WGQXBE3gLj" title="Shares issued">50,000</span> shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHG5SXJPuGm" title="Debt instrument periodic payment">5,000</span>. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHxJe28u5Dmj" title="Share price">1.10</span> per share for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGDwBaxumV3h" title="Shares issued value">55,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_z6jNcSTFuXMh" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zub5j5SSxMQa" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230605__20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zVNbzzklpj5l" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 6, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zf8Gi8TK8qt8" title="Warrants to purchase">150,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zY1q0JK9RDm9" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zaUrNO8y4FI4" title="Consideration paid">150,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 7, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zUJJ5akNgZT9" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zVutgnWML8Cg" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230607__20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zaN4XpWYZVpc" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 8, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zQrKKkGsJsBb" title="Warrants to purchase">24,500</span> shares of common stock with an exercise price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zdnv1zntA9Dj" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230608__20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zpMgNZqnLUIa" title="Consideration paid">24,500</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zCYqIfjAz8aa" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zUh2i1yMhKIe" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230621__20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zIVFauNt2ove" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_z9BNcCJP6mgj">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with an exercise price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zBpXeyqVUVm8">1.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zWaZYXV2jYC2">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXHNrXt02Khj" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zLbMrMssmWTb" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230627__20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zU7og6teHefl" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (“Greentree” and the “Service Agreement”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company agreed to issue Greentree <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zqnJqnyOwTNc" title="Shares issued in consideration">75,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement, and to pay Greentree $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zdn5lF3zxwAc" title="Paid in cash">40,000</span> in cash, payable as follows: <span id="xdx_901_eus-gaap--CommonStockConversionFeatures_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_z3xVcK2VVFMh" title="Settlement description">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024.</span> We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree’s activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zbyTuSehV7ie" title="Share price">1.13</span> per share for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z9UTw6OT4K37" title="Shares issued value">84,750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2023, the Company executed a Summary of Terms and Conditions (“Consulting Agreement”) with Gene Johnston (“Johnston”) continuing his appointment as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Consulting Agreement, the Company issued Johnston <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zcDvzDIjKOa6" title="Stock issued during period, shares">50,000</span> shares of the Company’s common stock and $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ztoIyVlgh7fc" title="Stock issued during period, value">2,000</span> per month. The Consulting Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (“Luca”), to provide certain management and consulting services to the Company during the term of the agreement, which is for three months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zl7YgAYht6p1" title="Stock issued during period, shares">200,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement and to pay Luca $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zNirJIEcmDnk" title="Stock value paid in cash">15,000</span> in cash, payable as follows: <span id="xdx_90A_eus-gaap--CommonStockConversionFeatures_c20231010__20231010__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zejb8t5qEro2" title="Settlement description">(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.</span> The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_z4PB9KJgTdcd" title="Stock issued price per share">0.63</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zxSh3dHCjALc" title="Stock issued during period, value">126,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2023, we entered into an Influencer Agreement with Jason Szkup (“Scoop”) to promote its products or services through social media platforms and other online channels, In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Scoop $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKUUlqKYRaTf" title="Shares issued">10,000</span> in cash and issue <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmUQdM8Mp66b" title="Shares issued">30,000</span> shares. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTLtFl5RPhIc" title="Share price">0.58</span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPiYX3VNE9Ih" title="Shares issued value">17,400</span>. The Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2023, the Board of Directors appointed Dr. Douglas Christianson, ND (“Dr. Christianson”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Dr. Christianson’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “Dr. Christianson Consulting Agreement”), with Dr. Christianson, whereby the Company agreed to issue Dr. Christianson <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20231101__srt--TitleOfIndividualAxis__custom--DrDouglasChristiansonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zx9J4MyqyDhc" title="Shares issued">50,000</span> shares. The Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The Company will reimburse Dr. Christianson for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231101__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZjRaU3QCYVa" title="Share price">0.58</span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231101__20231101__srt--TitleOfIndividualAxis__custom--DrDouglasChristiansonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcIEoytOWZO1" title="Shares issued value">29,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2023, we renewed a Consulting Agreement with PHX Global, LLC (“PHX”), which is owned by Peter “Casey” Jensen, who is a member of the Board of Directors of American International. Pursuant to the Consulting Agreement, PHX agreed to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231115__20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8WPKGVBgNy7" title="Shares issued">200,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zY6bHaUDL9Hk" title="Share price">0.47</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231115__20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxnfKHk6AROb" title="Shares issued value">94,000</span>. PHX is a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2023, the Company entered into a Marketing Agreement with Marius Pharmaceuticals (“Marius”) to market and sell KYZATREX®, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, ‘PRIME’ by MangoRx. During the Term, Marius grants to MangoRx a non-exclusive, non-transferable, royalty-free license to use the Marius Marks in the United States (the “Territory”) for the sole purpose of the Permitted Purpose. The term of the initial agreement is for two years, automatically renewable for successive one year terms, subject to certain performance targets as agreed upon each year. As consideration for the license granted herein, MangoRx shall issue to Marius one hundred thousand (<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231211__20231211__srt--TitleOfIndividualAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztjkoHXW1uB7" title="Shares issued">100,000</span>) shares of the Company’s common stock (the “Marius Shares”). The Marius Shares shall be issued to Marius upon signing of this Agreement and shall be deemed fully earned upon signing this Agreement. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231211__dei--LegalEntityAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgrNGLqHyAU4" title="Share price">0.58</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231211__20231211__dei--LegalEntityAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzo3aG4wBoN9" title="Shares issued value">58,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2023 the Company sold <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd5jhsqRTTO7" title="Number of shares sold">4,000,000</span> shares of its common stock at a price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2y5dOhx0ylb" title="Share price">0.30</span> per share to investors in connection with a follow on offering for gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKncC2ngJMIg" title="Gross proceeds">1,200,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company granted a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zKw508wowOqb" title="Number of options">1,250,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zc4st4tZsPui" title="Number of options granted">750,000</span> were granted to Jacob Cohen, the Company’s CEO, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zSbxjsIozADl" title="Number of options granted">500,000</span> were granted to Jonathan Arango, the Company’s then President and then COO, related to their respective employment agreement. The options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z183VpQZPRXf" title="Exercise price">1.10</span> per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zip6xXH0MHF7" title="Vesting term">three years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zW9QWfFiKx69" title="Number of options">150,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer, the Company’s COO, related to her employment agreement. The options have an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfTEwYi8Ql0i" title="Exercise price">1.10</span> per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20230501__20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxaLtQF1uoB1" title="Vesting term">three years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2023, the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zZRHOXIVwFl6" title="Number of options">1,250,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan to Jacob Cohen, the Company’s CEO, related to his employment agreement. The options have an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL2ty1aquUZ1" title="Exercise price">0.32</span> per share, an original life of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20231228__20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFqByADpMwKi" title="Vesting term">five years</span> and vested at the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zCkElpPppIna" title="Share based compensation">624,463</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJQ0ua9gIWn3" title="Share based compensation">82,267</span>, respectively, has been recorded and included as stock-based compensation expense on the statement of operations for the year-ended December 31, 2023 and within general and administrative expense for year-ended December 31, 2022. Mr. Cohen, Mr. Arango (former President and Director) and Ms. Hammer are related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zot1UgKJU1p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock options activity: The following table summarizes common stock options activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_z6LqqJyi6g5h" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zoRzCSb8A489" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zirRBPCfqHmf" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zYqIoUM65yia" style="width: 14%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zbLrMOnVd4o7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zRzJHlSbDx0k" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zYhmnC86xnEf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zKv2ezisJHMh" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zLmSZSEz9KT8" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zll1Tr17KxMf" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zEm1kxhUMsr4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z8qGKCKfNy5f" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zKgUhSxh4o6e" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zHrx0OHNOEn5" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_zH4u28O7uV3f" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zfoVnffykgKf" style="text-align: right" title="Options, Granted">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zHiDh2Vr0W0d" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_znorUnwfH1F9" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zSPkJjJlGNqg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zaXqknCRgQZ9" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zk3iaE8Q3sic" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zon7wAzx8uVh" style="text-align: right" title="Options, Outstanding Ending Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zdwG2LTbm0Ih" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zQZ7MPF1RJz5" style="text-align: right" title="Options, Exercisable Ending Balance">1,812,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_z4c3cT2WU9g3" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.73</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z81ixy44Jz0k" style="width: 13%; text-align: right" title="Weighted Average Outstanding Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBOJheSCy9P7" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkqhL8AJBKoc" title="Options Term">4.28</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7KoUyfqwNs1" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z72ShWh159Md" style="width: 13%; text-align: right" title="Exercisable Ending Balance">562,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z0D9jLVhd0x7" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6daUvGPpBgb" style="text-align: right" title="Weighted Average Outstanding Ending Balance">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsTr37Vv3vpk" style="text-align: right" title="Outstanding Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsa11jJNZYT" title="Options Term">5.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT0Lvdjm89j" style="text-align: right" title="Weighted Average Exercisable Price Ending Balance">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjG0AYIYJ1Ae" style="text-align: right" title="Exercisable Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOagwkiiO0N" style="text-align: right" title="Weighted Average Exercisable Price Ending Balance">0.32</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zI1V7pbGbqEe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the fair value of options outstanding was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231_zy2cpTm2NWe8" title="Fair value of options outstanding">573,202</span>. The aggregate initial fair value of the options measured on the grant date of August 31, 2022, May 1, 2023 and December 28, 2023 was calculated using the Black-Scholes option pricing model based on the following assumption:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2E0r2ygbfzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zOikQmEJqsY8" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zHSVnODuBs7g" title="Fair value of common stock on measurement date">1.00</span> – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zVbz7iRt5L8i" title="Fair value of common stock on measurement date">0.32</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z0Z00OeU8Jz6" title="Risk free interest rate">3.83</span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zh7gE12ylDJ1" title="Risk free interest rate">3.30</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zondJNFBs5A2" title="Volatility">232.05</span>% <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zn7DqaZmhVI8" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zM0fvH7IaHw6" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zLzJYK8KBhYc" title="Expected term">6.0</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zh3hA9rE1xz6" title="Expected term">3.5</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term</span></td></tr> </table> <p id="xdx_8A3_zJFbKpSbVvol" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9KGQG2Ghzmi" title="Warrants issued">87,500</span> shares of common stock with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFQnN0UjZc1c" title="Exercise price">5.00</span> per share, which are exercisable six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230320__20230320_z259YH0JLJY9" title="Fair value of warrants">31,995</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As additional consideration in connection with the follow on offering, upon the closing of the follow on offering, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the secondary offering, warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuOH4P2BitN2" title="Warrants issued">280,000</span> shares of common stock with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zS4APaCHm9ti" title="Exercise price">0.38</span> per share, which are exercisable six months after the effective date of the registration statement filed in connection with the follow on offering (December 19, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvr3DQ2FX0Uk" title="Fair value of warrants">271,216</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the fair value of warrants outstanding to investors was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zg4lHAVlvdC2" title="Fair value of warrants outstanding">852,480</span> and $<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zJfstESt9xO5" title="Fair value of warrants outstanding">581,264</span>, respectively. Because the warrants vested immediately, the fair value was assessed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkYry3ZHtDa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock warrants activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zWHjx2Ym29W8" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zohZBoKiqn64" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT4A4jeuMdUh" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq0wZ6xyouFk" style="width: 14%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbdT7mhPJBDf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwq5HpI709zh" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwPkPP7uJYec" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk1cbh8PjLLi" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1375">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znXJ0x29uCX2" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkojCTRzumDk" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAxyYL5BzAx3" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEQevqQN5ov2" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjDK5HSmGWb" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYEjeV3Fu1ig" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl9yI0dDUJ3i" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlWosxsuqNm1" style="text-align: right" title="Warrants Granted">367,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz9T1m4v7zm4" style="text-align: right" title="Weighted Average Exercise Price Granted">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0S1WvYZ7m3c" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztUvixr5JcU2" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znwRBgXRBAZ1" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoFpIFTPBCQg" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1KIeEmBPjNh" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqmh9dYXwi1" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR9N6nzTfnH9" style="text-align: right" title="Warrants Outstanding, Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKvGmpageDgk" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zro3CKNMn2t6" style="text-align: right" title="Warrants Exercisable Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwlIK0luNm06" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.43</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2023, were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Warrant</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price Per Share</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231_zZB479TNrwAj" style="width: 38%; text-align: right" title="Weighted Average Exercise Price Exercised">1.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziomsEr4Ow9i" style="width: 26%; text-align: right" title="Outstanding and Vested Warrants Ending balance">1,343,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY4aEKRg5Gy" style="width: 26%; text-align: right" title="Outstanding and Vested Warrants Expected Term">2.07</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zmCXuPnX7OD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMwxIU6UjGC8" title="Warrants outstanding">1,063,000</span> shares of common stock are outstanding and vested, and the vested stock warrants have a weighted average remaining life of <span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLuXA5H5tgvk" title="Outstanding and vested warrants expected term">3.83</span> years.</span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6YPV4jfzJij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zALzPByUOqod" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in; width: 75%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zm2llRyS4SQ" title="Fair Value of Common Stock on measurement date">0.37</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zVjm8ReeeYOh" title="Fair Value of Common Stock on measurement date">0.97</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zGqrSIknTXX8" title="Risk-free interest rate">2.95</span>% to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOsYzuwPM358" title="Risk-free interest rate">4.00</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXRKfvZFhDUl" title="Volatility">81.92</span>% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zO6Mby341FE9" title="Volatility">169.22</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcw5sKh1T7B8" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM1wnsjAM7cd" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</span></td></tr> </table> <p id="xdx_8AF_zTMlMIo3SSf4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 10000000 10000000 0.0001 0.0001 200000000 200000000 0.0001 0.0001 21419500 21419500 13365000 13365000 100000 50000 1.00 100000 1.00 250000 25000 2000 1.00 25000 25000 1.00 25000 1.00 350000 1250000 4.00 5000000 100000 1.00 100000 100000 1.00 100000 25000 1.00 25000 25000 1.00 25000 75000 1.00 75000 100000 1.00 100000 25000 1.00 25000 150000 1.00 50000 300000 180000 1.00 180000 50000 1.10 55000 20000 1.10 22000 50000 5000 1.10 55000 25000 1.00 25000 150000 1.00 150000 75000 1.00 75000 24500 1.00 24500 100000 1.00 100000 100000 1.00 100000 100000 1.00 100000 75000 40000 (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024. 1.13 84750 50000 2000 200000 15000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. 0.63 126000 10000 30000 0.58 17400 50000 0.58 29000 200000 0.47 94000 100000 0.58 58000 4000000 0.30 1200000 1250000 750000 500000 1.10 P3Y 150000 1.10 P3Y 1250000 0.32 P5Y 624463 82267 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zot1UgKJU1p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock options activity: The following table summarizes common stock options activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_z6LqqJyi6g5h" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zoRzCSb8A489" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zirRBPCfqHmf" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zYqIoUM65yia" style="width: 14%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zbLrMOnVd4o7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zRzJHlSbDx0k" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zYhmnC86xnEf" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zKv2ezisJHMh" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zLmSZSEz9KT8" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zll1Tr17KxMf" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zEm1kxhUMsr4" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z8qGKCKfNy5f" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zKgUhSxh4o6e" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zHrx0OHNOEn5" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_zH4u28O7uV3f" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zfoVnffykgKf" style="text-align: right" title="Options, Granted">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zHiDh2Vr0W0d" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_znorUnwfH1F9" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zSPkJjJlGNqg" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zaXqknCRgQZ9" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zk3iaE8Q3sic" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zon7wAzx8uVh" style="text-align: right" title="Options, Outstanding Ending Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zdwG2LTbm0Ih" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zQZ7MPF1RJz5" style="text-align: right" title="Options, Exercisable Ending Balance">1,812,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_z4c3cT2WU9g3" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.73</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2023 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z81ixy44Jz0k" style="width: 13%; text-align: right" title="Weighted Average Outstanding Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBOJheSCy9P7" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkqhL8AJBKoc" title="Options Term">4.28</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7KoUyfqwNs1" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z72ShWh159Md" style="width: 13%; text-align: right" title="Exercisable Ending Balance">562,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z0D9jLVhd0x7" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6daUvGPpBgb" style="text-align: right" title="Weighted Average Outstanding Ending Balance">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsTr37Vv3vpk" style="text-align: right" title="Outstanding Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsa11jJNZYT" title="Options Term">5.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT0Lvdjm89j" style="text-align: right" title="Weighted Average Exercisable Price Ending Balance">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjG0AYIYJ1Ae" style="text-align: right" title="Exercisable Ending Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zOagwkiiO0N" style="text-align: right" title="Weighted Average Exercisable Price Ending Balance">0.32</td><td style="text-align: left"> </td></tr> </table> 1250000 1.10 1250000 1.10 133333 1.10 1250000 1.10 1400000 0.40 2650000 0.73 1812500 0.73 1.10 1400000 P4Y3M10D 1.10 562500 1.10 0.32 1250000 P5Y 0.32 1250000 0.32 573202 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2E0r2ygbfzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zOikQmEJqsY8" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zHSVnODuBs7g" title="Fair value of common stock on measurement date">1.00</span> – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zVbz7iRt5L8i" title="Fair value of common stock on measurement date">0.32</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z0Z00OeU8Jz6" title="Risk free interest rate">3.83</span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zh7gE12ylDJ1" title="Risk free interest rate">3.30</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zondJNFBs5A2" title="Volatility">232.05</span>% <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zn7DqaZmhVI8" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zM0fvH7IaHw6" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zLzJYK8KBhYc" title="Expected term">6.0</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zh3hA9rE1xz6" title="Expected term">3.5</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, in accordance with staff accounting bulletin (“SAB”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term</span></td></tr> </table> 1.00 0.32 0.0383 0.0330 2.3205 0.9254 0 P6Y P3Y6M 87500 5.00 31995 280000 0.38 271216 852480 581264 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zkYry3ZHtDa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock warrants activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zWHjx2Ym29W8" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zohZBoKiqn64" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT4A4jeuMdUh" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq0wZ6xyouFk" style="width: 14%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbdT7mhPJBDf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwq5HpI709zh" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwPkPP7uJYec" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk1cbh8PjLLi" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1375">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znXJ0x29uCX2" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkojCTRzumDk" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAxyYL5BzAx3" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEQevqQN5ov2" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjDK5HSmGWb" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYEjeV3Fu1ig" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl9yI0dDUJ3i" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlWosxsuqNm1" style="text-align: right" title="Warrants Granted">367,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz9T1m4v7zm4" style="text-align: right" title="Weighted Average Exercise Price Granted">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0S1WvYZ7m3c" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztUvixr5JcU2" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znwRBgXRBAZ1" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoFpIFTPBCQg" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1KIeEmBPjNh" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1403">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqmh9dYXwi1" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR9N6nzTfnH9" style="text-align: right" title="Warrants Outstanding, Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKvGmpageDgk" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zro3CKNMn2t6" style="text-align: right" title="Warrants Exercisable Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwlIK0luNm06" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.43</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2023, were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average Warrant</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price Per Share</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231_zZB479TNrwAj" style="width: 38%; text-align: right" title="Weighted Average Exercise Price Exercised">1.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziomsEr4Ow9i" style="width: 26%; text-align: right" title="Outstanding and Vested Warrants Ending balance">1,343,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY4aEKRg5Gy" style="width: 26%; text-align: right" title="Outstanding and Vested Warrants Expected Term">2.07</td><td style="width: 1%; text-align: left"> </td></tr> </table> 2210070 1.00 -210070 1.00 2000000 1.00 2000000 1.00 367500 1.22 -1024500 1.00 1343000 1.43 1343000 1.43 1.43 1343000 P2Y25D 1063000 P3Y9M29D <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6YPV4jfzJij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zALzPByUOqod" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in; width: 75%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zm2llRyS4SQ" title="Fair Value of Common Stock on measurement date">0.37</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zVjm8ReeeYOh" title="Fair Value of Common Stock on measurement date">0.97</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zGqrSIknTXX8" title="Risk-free interest rate">2.95</span>% to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zOsYzuwPM358" title="Risk-free interest rate">4.00</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXRKfvZFhDUl" title="Volatility">81.92</span>% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zO6Mby341FE9" title="Volatility">169.22</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcw5sKh1T7B8" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM1wnsjAM7cd" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</span></td></tr> </table> 0.37 0.97 0.0295 0.0400 0.8192 1.6922 0 P5Y <p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zwg4YWuBacV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82C_z7ctyIHb7Lwg">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying financials, the Company had a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_z8K7eeJhb2G" title="Net loss">9,212,417</span> for the year ended December 31, 2023 and an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_z7opfbZ8hqBg" title="Accumulated deficit">11,228,173</span> as of December 31, 2023. The Company will need to raise additional capital to successfully execute its business plan of which there can be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> -9212417 -11228173 <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zE1tsvFjXMr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_821_zffhVWlflNJ5">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has a lease for an office in Dallas, Texas classified as operating leases under ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “Landlord”) to lease and occupy approximately <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20220928_zxisO0TWsHwe">2,201</span> square feet of office space located at 15110 Dallas Parkway, Suite 600, Dallas, Texas 75248 to serve as the Company’s main headquarters (the “<span style="text-decoration: underline">Lease Agreement</span>”). The Lease Agreement has a term of thirty-eight (<span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zwRjY14ix9f1" title="Lease term">38</span>) months and has a monthly base rent of $<span id="xdx_90F_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928_zNQJnq4wM9w7" title="Base rent">5,777.63</span>, or $31.50 per square foot, the from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term (the “<span style="text-decoration: underline">Base Rent</span>”). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_900_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zaqa1uJqhpNd" title="Percentage of proportionate rent">2.45</span>% (the “<span style="text-decoration: underline">Proportionate Rent</span>”). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month’s Base Rent along with a security deposit equal to $<span id="xdx_904_eus-gaap--PaymentsForRent_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zxwY6oex2Yh9" title="Base rent">16,942</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of <span id="xdx_90E_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zBRAZ3Qaaq6l" title="Percentage of incremental borrowing rate">8</span>% to estimate the present value of the right-of-use liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has right-of-use assets of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231_zV4ye8jdqyWg">119,262</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and operating lease liabilities of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20231231_znHdclZgTyw">128,679 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of December 31, 2023. Operating lease expense for the year ended December 31, 2023 was $<span id="xdx_905_eus-gaap--OperatingLeaseCost_c20230101__20231231_z7tq9XRgdAh3">65,274</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company has recorded $<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_c20230101__20231231_z3wGL3Utngnj">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in impairment charges related to right-of-use assets during the year ended December 31, 2023.</span></p> <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zm8glGephod6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zrYnUv7f7tcc" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity of Lease Liabilities at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zSs6jJ1EXoyf" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zqq4LArcq9ud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">71,716</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzowI_zoVmCtDs3QAj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_maLOLLPzowI_zzsyuc3dLTRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Later years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_znbWASAfl95b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zXRsNpxf4lt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zPhqmOVynySj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zXEAO3KZDF6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2201 P38M 5777.63 0.0245 16942 0.08 119262 128679 65274 0 <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zm8glGephod6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zrYnUv7f7tcc" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity of Lease Liabilities at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zSs6jJ1EXoyf" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zqq4LArcq9ud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">71,716</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzowI_zoVmCtDs3QAj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_maLOLLPzowI_zzsyuc3dLTRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Later years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_znbWASAfl95b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zXRsNpxf4lt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zPhqmOVynySj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 71716 67589 139305 10626 128679 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zguIH6ifWFF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 - <span id="xdx_82B_zsNnmBt4dwhi">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which significantly changed U.S. tax law. The Act lowered the Company’s U.S. statutory federal income tax rate from <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MaximumMember_z9wiAI2R6vWg" title="Statutory federal income tax rate, percentage">35</span>% to <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MinimumMember_zrqxZTs1j9Ij" title="Statutory federal income tax rate, percentage">21</span>% effective January 1, 2018, while also imposing a deemed repatriation tax on previously deferred foreign income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increased the Company’s deferred tax asset related to the Company’s net operating loss by approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231_zYOfC2qc3TCi" title="Deferred tax asset net operating loss">9,212,417</span> and increased the Company’s valuation allowance by approximately $<span id="xdx_905_ecustom--DecreaseInDeferredTaxAssetsValuationAllowance_iI_c20231231_zdv8uo952x94" title="Decrease in deferred tax assets, valuation allowance">9,212,417</span> resulting in no impact to the Company’s financials.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2023, and 2022 we have not recorded any uncertain tax positions in our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective US Federal Income Corporate Tax Rates for 2023 and 2022 are <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20231231_zEikkjW6XUll" title="US federal income corporate tax rates">21</span>% and <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zUbrzcO5BAYe" title="US federal income corporate tax rates">21</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20231231_zpDAP1kTPJt9" title="Net operating loss carry forwards">11,228,173</span> at December 31, 2023 that do not expire. However, utilization of these losses may be limited pursuant to Section 382 of the Internal Revenue Code due to subsequent stock issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z3R4amQ8DZX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a deferred tax asset as shown in the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B9_zgUaz5mQiwMi" style="display: none">SCHEDULE OF DEFERRED TAX ASSET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zknf8sbPGFf" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ending December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_zoRxFhB6Cil2" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ending December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_z0Arln50awcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Deferred Tax Asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">11,228,173</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,015,756</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_z6WDT0a2b5jj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Valuation Allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,228,173</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,015,756</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_zNA513aq0S03" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Deferred Tax Asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">—</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zvYOcvB3v1Ng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.35 0.21 9212417 9212417 0.21 0.21 11228173 <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z3R4amQ8DZX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a deferred tax asset as shown in the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B9_zgUaz5mQiwMi" style="display: none">SCHEDULE OF DEFERRED TAX ASSET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zknf8sbPGFf" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ending December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_zoRxFhB6Cil2" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ending December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_z0Arln50awcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Deferred Tax Asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">11,228,173</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">2,015,756</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_z6WDT0a2b5jj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Valuation Allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,228,173</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,015,756</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_zNA513aq0S03" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Deferred Tax Asset</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">—</span></td><td style="text-align: left"> </td></tr> </table> 11228173 2015756 11228173 2015756 <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zepIdGEjkEoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_82A_zswvR9pW8GBb">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 2, 2024, we entered into a Consulting Agreement with G&amp;P General Consulting (“G&amp;P”), Pursuant to the Consulting Agreement, G&amp;P agreed to provide consulting and general business advisory services as it relates to the expansion of the Company’s products into additional international territory’s, including, but not limited to, the United Arab Emirates (UAE), China, Japan, Korea, and in certain regions of Asia and additional services as reasonably requested by the Company during the Term of this Agreement as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued G&amp;P <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240102__20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zlCzjxxZMga1" title="Number of restricted common shares issued">250,000</span> shares of restricted common stock. G&amp;P will receive an additional <span id="xdx_90D_ecustom--AdditionalStockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240102__20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zX2aoa8F5nyk" title="Number of additional restricted common shares issued">500,000</span> shares in 90 days, if the agreement is still in place. The Consulting Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zG9K25pmdYLf" title="Shares issued price per share">0.28</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240102__20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_z5iKILxDb3v1" title="Number of restricted common shares issued, value">70,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 10, 2024, we renewed a Consulting Agreement with Luca Consulting, LLC (“Luca”), to provide certain management and consulting services to the Company during the term of the agreement, which is for three months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240110__20240110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zDn8hFOMNqA" title="Number of restricted common shares issued">200,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement and to pay Luca $<span id="xdx_909_ecustom--AgreementPayableInCash_c20240110__20240110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_z3gtIodIZfyk" title="Agreement payable in cash">15,000</span> in cash, payable as follows: <span id="xdx_906_ecustom--ConsultingAgreementDescription_c20240110__20240110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zgyV4vRH1Moj" title="Consulting agreement description">(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters.</span> The shares were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zNl5N2GjQW59" title="Shares issued price per share">0.28</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240110__20240110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_z4jk9buDgAD9" title="Number of restricted common shares issued, value">56,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 11, 2024, we entered into a Consulting Agreement with First Level Capital (“First Level”), to provide certain management and consulting services to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued an initial <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240111__20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zjTEfgIEWdIj" title="Number of restricted common shares issued">250,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement, an additional <span id="xdx_903_ecustom--AdditionalStockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240111__20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zvwowKt6hV04" title="Number of additional restricted common shares issued">250,000</span> shares of the Company’s restricted common stock before the end of the term of the agreement and to pay First Level $<span id="xdx_909_ecustom--AgreementPayableInCash_c20240111__20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zHUBJSoOuw97" title="Agreement payable in cash">60,000</span> in cash, payable as follows: <span id="xdx_906_ecustom--ConsultingAgreementDescription_c20240111__20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zEOIoSLwTED4" title="Consulting agreement description">(a) $60,000 on the signing of the agreement; (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters.</span> The initial shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zux2JZV5jsZb" title="Shares issued price per share">0.28</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240111__20240111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zv9qEAc2l6ib" title="Number of restricted common shares issued, value">70,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2024, the Underwriters in the follow-on offering notified the Company that they were exercising their over-allotment option in full to purchase an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zW3i5aVcV3J1" title="Number of shares issued">600,000</span> shares of common stock, which sale closed on January 22, 2024. The net proceeds to the Company from the sale of the <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_znryaiMCCPmd" title="Number of shares issued">600,000</span> shares of common stock, after deducting underwriting discounts and expenses, was approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240118__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_ztipcrxw6WVc" title="Proceeds from sale of common stock">160,000</span>. Inclusive of the full exercise of the over-allotment option, a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRk6LqUBMhOa" title="Number of shares issued">4,600,000</span> shares of common stock were issued and sold in the follow-on offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to the Representative for the purchase of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkzXUuTq8C76" title="Number of warrants to purchase of common stock">42,000</span> shares of its common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zH0RhJjzAj69" title="Exercise price per share">0.375</span>, subject to adjustments (the “<span style="text-decoration: underline">Warrant</span>”). The Warrant is exercisable at any time and from time to time, in whole or in part, until December 14, 2028, and may be exercised on a cashless basis. The Warrant also includes customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the Warrant. The Warrant and the shares of common stock underlying the Warrant were registered as a part of the follow-on registration statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On March 21, 2024, we entered into Amendment to the of January 10, 2024 consulting agreement with Luca extending the agreement for an additional 6 months (the “Luca Amendment”). In consideration for entering into the Luca Amendment, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240321__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zKWp94v8iujk" title="Number of restricted common shares issued">500,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the Luca Amendment and agreed to continue to pay Luca $<span id="xdx_90B_ecustom--AgreementPayableInCash_c20240321__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zmnKmCbjJrHk" title="Agreement payable in cash">5,000</span> in in cash on the tenth of each month throughout the remainder of the agreement. The shares were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_za2Y156GgkO3" title="Shares issued price per share">0.1975</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240321__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zH04G50mLgtb" title="Number of restricted common shares issued, value">98,750</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On March 21, 2024, we entered into a Consulting Agreement with Zvonimir Moric (the “Zee”). Pursuant to the consulting agreement, Zee agreed to provide consulting and general business advisory services as it relates to making introductions to strategic partners to expand the sales of the Company’s products and additional services as reasonably requested by the Company during the Term of this Agreement as reasonably requested by the Company during the term of the agreement, which is for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Zee <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240321__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_zPCiQWRQ1vXj" title="Number of restricted common shares issued">150,000</span> shares of restricted common stock. The Consulting Shares were issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_zXFqVLYhXief" title="Shares issued price per share">0.1975</span> per share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240321__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_znlWdqCirkb8" title="Number of restricted common shares issued, value">29,625</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2024, the Company borrowed $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20240401__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--RoninEquityPartnersMember_z6Ii94hbI3sg" title="Borrow amount">37,500</span> from Ronin Equity Partners, which is owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman. The amount borrowed is payable on demand and does not accrue interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2024, the Company borrowed $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_c20240318__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--CohenEnterprisesIncMember_zbZtK7sGggG8" title="Borrow amount">50,000</span> from Cohen Enterprises, Inc. , which is owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman. The amount borrowed is payable on demand and does not accrue interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On March 25, 2024, at a Special Meeting of the stockholders of the Company,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the stockholders of the Company approved a First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan (“<span style="text-decoration: underline">First Amendment</span>” and the Mangoceuticals, Inc. 2022 Equity Incentive Plan, as amended by the First Amendment, the “<span style="text-decoration: underline">2022 Plan</span>”). The First Amendment was originally approved by the Board of Directors of the Company on February 26, 2024, subject to stockholder approval and the First Amendment became effective at the time of stockholder approval. <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240325__20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember_z9QmZ2ogwhi" title="Number of stock available for awards description">The First Amendment increased the number of shares of common stock available for awards under the Incentive Plan, such that currently, subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2022 Plan is currently the sum of (i) <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember_zab7lysv4155" title="Number of stock issued">10,000,000</span>, and (ii) an automatic increase on April 1st of each year for a period of nine years commencing on April 1, 2024 and ending on (and including) April 1, 2032, in an amount equal to the lesser of (x) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; and (y) <span id="xdx_901_eus-gaap--SharesIssued_iI_c20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5OYIdegOem5" title="Number of stock issued">2,000,000</span> shares of common stock; provided, however, that the Board may act prior to April 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. This is also known as an “evergreen” provision. Notwithstanding the foregoing, no more than a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240325__20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFygDtKCkv87" title="Number of stock issued granted">26,000,000</span> shares of common stock (or awards) may be issued or granted under the 2022 Plan in aggregate, and no more than <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240325__20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg2P3cTTd1G2" title="Number of stock issued exercise">26,000,000</span> shares of common stock may be issued pursuant to the exercise of Incentive Stock Options</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also at the Special Meeting, the stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding shares of our common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240325__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgbqp4UQADTb" title="Common stock, par value">0.0001</span> per share, by a ratio of between one-for-two to one-for-fifty inclusive, with the exact ratio to be set at a whole number to be determined by the Company’s Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to March 25, 2025. No formal determination has been made by the Board of Directors of the Company regarding the reverse stock split ratio, whether or not to move forward with a reverse stock split, or the timing thereof.</span></p> 250000 500000 0.28 70000 200000 15000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. 0.28 56000 250000 250000 60000 (a) $60,000 on the signing of the agreement; (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters. 0.28 70000 600000 600000 160000 4600000 42000 0.375 500000 5000 0.1975 98750 150000 0.1975 29625 37500 50000 The First Amendment increased the number of shares of common stock available for awards under the Incentive Plan, such that currently, subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2022 Plan is currently the sum of (i) 10,000,000, and (ii) an automatic increase on April 1st of each year for a period of nine years commencing on April 1, 2024 and ending on (and including) April 1, 2032, in an amount equal to the lesser of (x) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; and (y) 2,000,000 shares of common stock; provided, however, that the Board may act prior to April 1st of a given year to provide that the increase for such year will be a lesser number of shares of common stock. This is also known as an “evergreen” provision. Notwithstanding the foregoing, no more than a total of 26,000,000 shares of common stock (or awards) may be issued or granted under the 2022 Plan in aggregate, and no more than 26,000,000 shares of common stock may be issued pursuant to the exercise of Incentive Stock Options 10000000 2000000 26000000 26000000 0.0001 490243 739006 14019 18501 13299 60953 517561 818460 1749 28752 28752 3313 96129 90011 119262 14610000 14703324 215391 16942 16942 16942 16942 15237827 1050793 718650 140765 4687 6595 187500 67428 63718 400000 1378265 211078 30117 64961 30117 64961 1408382 276039 0.0001 0.0001 6000 6000 2145 2145 0 0 0.0001 0.0001 6250000 6250000 980000 980000 0 0 98 98 0.0001 0.0001 200000000 200000000 29135451 29135451 21419500 21419500 2913 2142 514496 1000000 30300213 12000785 -15986733 -11228173 -1166 13829821 774754 -376 13829445 774754 15237827 1050793 163163 141237 377258 241959 29665 25592 50460 49345 63706 28515 109608 48285 69792 87130 217190 144329 850704 567655 1622662 1951614 259105 374396 552314 396094 229244 797263 1081627 912997 40000 90500 183000 519465 859380 549574 1313845 1215542 2238433 2379388 4753448 4995712 -2168641 -2292258 -4536258 -4851383 8233 6473 222678 222678 -222678 8233 -222678 6473 -2391319 -2284025 -4758936 -4844910 -2391319 -2284025 -4758936 -4844910 -340 -376 -2390979 -2284025 -4758560 -4844910 -0.09 -0.09 -0.14 -0.14 -0.19 -0.19 -0.33 -0.33 26099532 26099532 15772348 15772348 24577289 24577289 14500230 14500230 -2391319 -2284025 -4758936 -4844910 -1096 -1166 -2392415 -2284025 -4760102 -4844910 -340 -376 -2392075 -2284025 -4759726 -4844910 13365000 1337 2628449 -2015756 614030 700000 70 699930 700000 1250000 125 4999875 5000000 1760 1760 64271 64271 -2560885 -2560885 15315000 1532 8394285 -4576641 3819176 375000 37 386963 387000 1024500 102 1024398 1024500 -8233 -8233 64271 64271 -2284025 -2284025 16714500 1671 9861684 -6860666 3002689 21419500 2142 12000785 -11228173 774754 1600000 160 416340 416500 600000 60 179940 180000 37965 37965 -70 -70 -2367581 -36 -2367617 23619500 2362 12635030 -13595754 -70 -36 -958468 23619500 2362 12635030 -13595754 -70 -36 -958468 2500 514496 -1000000 1985504 1500000 222678 222678 980000 98 14209902 14210000 2642308 264 808136 808400 950000 95 388175 388270 -355 -390500 -390500 1923643 192 390308 390500 50980 50980 -1096 -1096 -2390979 -340 -2391319 2145 980000 98 29135451 2913 514496 -1000000 30300213 -15986733 -1166 -376 13829445 2145 980000 98 29135451 2913 514496 -1000000 30300213 -15986733 -1166 -376 13829445 -4758936 -4844910 9429 12306 1224900 1087000 -6473 88945 128542 -18387 222678 -4482 23494 -47654 41015 -29251 -27082 577885 96530 -31134 -27862 -1908 3408 -2568367 -3588886 3519 65000 65000 -3519 187500 568270 5000000 1500000 1024500 78260 89200 2255770 5857040 -247597 2264635 739006 682860 -1166 490243 2947495 14610000 390500 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zsOu3ZQIR5B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_826_zXOzAUTOo4xk">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. (“<span style="text-decoration: underline">Mangoceuticals</span>” or the “<span style="text-decoration: underline">Company</span>”), was incorporated in the State of a Texas on October 7, 2021, with the intent of focusing on developing, marketing, and selling a variety of men’s wellness products and services via a telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (“<span style="text-decoration: underline">ED</span>”), hair loss and testosterone replacement or enhancement therapies. In this regard, Mangoceuticals has developed and is commercially marketing a new brand of ED products under the brand name “<span style="text-decoration: underline">Mango</span>” and a new brand of hair loss products under the brand name “<span style="text-decoration: underline">Grow.</span>” These products are produced at a compounding pharmacy using a proprietary combination of U.S. Food and Drug Administration (“<span style="text-decoration: underline">FDA</span>”) approved ingredients which are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling these branded ED and hair loss products exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>. Product availability varies by state, details are available on our website.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Public Offering. </i>In March 2023, the Company completed an initial public offering (the “<span style="text-decoration: underline">IPO</span>”), in which the Company issued and sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zlyf5EF9mG9i" title="Issuance of shares">1,250,000</span> shares of authorized common stock for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGhA3Ty0QsIh" title="Share issued price per share">4.00</span> per share for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVucO1be0Gq5" title="Net proceeds from issuance of common stock">4.35</span> million, after deducting underwriting discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate prospectus (the “<span style="text-decoration: underline">Resale Prospectus</span>”) the Company registered the sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zN14rwrFImS9" title="Sale of stock, shares">4,765,000</span> shares of common stock, including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zsFlRVfR9Kr" title="Issuance of shares">2,000,000</span> shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zlcqR00Y4d2e" title="Share issued price per share">1.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 15, 2023, we entered into another underwriting agreement (the “<span style="text-decoration: underline">Underwriting Agreement</span>”) with Boustead Securities, LLC (“<span style="text-decoration: underline">Boustead</span>”), as representative of certain underwriters (the “<span style="text-decoration: underline">Underwriters</span>”), relating to a public offering of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231215__20231215__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zHjif7prvUBc" title="Issuance of shares">4,000,000</span> shares of the Company’s common stock to the Underwriters at a purchase price to the public of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20231215__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze9tMLzjTIQi" title="Purchase price">0.30</span> per share and also granted to the Underwriters a 45-day option to purchase up to <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231215__20231215__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_ziiY5mxxosA2" title="Granted to purchase of shares">600,000</span> additional shares of common stock, solely to cover over-allotments, if any, at the public offering price less the underwriting discounts (the “<span style="text-decoration: underline">Follow On Offering</span>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Follow On Offering closed on December 19, 2023. As a result, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4pPxDXaoHkf" title="Issuance of shares">4,000,000</span> shares of its common stock for total gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmgFQjxGsgq4" title="Issuance of shares">1.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds to the Company from the Offering, after deducting the underwriting discounts and commissions and offering expenses, were approximately $<span id="xdx_90E_ecustom--OfferingExpense_pn5n6_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBDv3AZ9kCza" title="Offering expense">1.0</span> million. The Company used the net proceeds from the Offering to finance the marketing and operational expenses associated with the planned marketing of its Mango ED and GROW hair growth products, to hire additional personnel to build organizational talent, to develop and maintain software, and for working capital and other general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2023, pursuant to the Underwriting Agreement, the Company issued a common stock purchase warrant to Boustead for the purchase of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231219__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKwmsoTJm7Mj" title="Number of warrants to purchase of common stock">280,000</span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231219__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zkr8qB0yag86" title="Exercise price per share">0.38</span> per share, subject to adjustments. The warrant is exercisable at any time and from time to time, in whole or in part, until December 14, 2029, and may be exercised on a cashless basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2024, the Underwriters notified the Company that they were exercising their over-allotment option in full to purchase an additional <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zAegG3WMGuHb" title="Number of shares issued">600,000</span> shares of common stock, which sale closed on January 22, 2024. The net proceeds to the Company from the sale of the <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zUuM89wJB5nh" title="Number of shares issued">600,000</span> shares of common stock, after deducting underwriting discounts and expenses, was approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zG9poSjOwNuk" title="Proceeds from sale of common stock">160,000</span>. Inclusive of the full exercise of the over-allotment option, a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z5qfqjVPCMzc" title="Number of shares issued">4,600,000</span> shares of common stock were issued and sold in the Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to Boustead for the purchase of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zROvy01yw3Md" title="Number of warrants to purchase of common stock">42,000</span> shares of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zcdDmlFLOQV3" title="Exercise price per share">0.375</span>, subject to adjustments. The warrant is exercisable at any time and from time to time, in whole or in part, until December 14, 2028, and may be exercised on a cashless basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2024 (the “<span style="text-decoration: underline">Initial Closing Date</span>”), we agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024 (as amended from time to time, the “<span style="text-decoration: underline">SPA</span>”), with an institutional accredited investor (the “<span style="text-decoration: underline">Purchaser</span>”), pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5UUf37fWTk6" title="Number of shares issued">1,500</span> shares of newly designated Series B Convertible Preferred Stock (“<span style="text-decoration: underline">Series B Preferred Stock</span>”) of the Company for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zG0gbl3KC7h4" title="Number of shares issued, value">1,650,000</span>, and warrants (the “<span style="text-decoration: underline">Initial Warrants</span>”), to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsirPmbQFLT1" title="Warrants to purchase common stock">3,300,000</span> shares of common stock for an aggregate purchase price of $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueWarrants_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5unNvBBcuvc" title="Purchase price of warrants">1,500,000</span>. On the Initial Closing Date, the Company sold the Purchaser <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6hEvI2iOz21" title="Number of shares sold">500</span> shares of Series B Preferred Stock (the “<span style="text-decoration: underline">Initial Closing Shares</span>”) and the Initial Warrants, for an aggregate of $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgOrYulRYWmk" title="Aggregate amount for warrant">500,000</span>. The Initial Warrants are exercisable on or after October 4, 2024, and for five years thereafter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also on the Initial Closing Date, the Company entered into an Equity Purchase Agreement (the “<span style="text-decoration: underline">ELOC</span>”) with the Purchaser pursuant to which the Purchaser committed to purchase up to $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zkwkInbxHsEh" title="Number of shares issued, value">25,000,000</span> (the “<span style="text-decoration: underline">Maximum Amount</span>”) of the Company’s Common Stock (the “<span style="text-decoration: underline">Financing</span>”). On the Initial Closing Date, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zp0BWKCWG7ie" title="Number of shares issued">1,000,000</span> shares of the Company’s common stock to the Purchaser as a commitment fee (the “<span style="text-decoration: underline">Commitment Shares</span>”). The Commitment Shares were valued at $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240405__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommitmentSharesMember_zjX0RZ23hdtl" title="Share price">0.2149</span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommitmentSharesMember_zEVHio22s1A1" title="Number of shares issued, value">214,900</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2024, the Company partially closed a planned second closing under the SPA (the “<span style="text-decoration: underline">Second Closing</span>”) whereby the Purchaser paid $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbewvuNIfoy1" title="Shares paid amount">150,000</span> to the Company in consideration for <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9eRRjBAhfhh" title="Number of shares sold">150</span> shares of Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2024, the Company closed the remaining portion of the Second Closing whereby the Purchaser paid $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240517__20240517__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbWHeazRiXP6" title="Sale of stock value">100,000</span> to the Company in consideration for an additional <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240517__20240517__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPJNIFJR4x2h" title="Number of shares sold">100</span> shares of Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfSharePurchaseAgreementTableTextBlock_zbKV1LJeKsGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1 (the “<span style="text-decoration: underline">Amendment</span>”), which amended the SPA to, adjust the closings which were to take place under the SPA as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zHInElHXCBee">SCHEDULE OF SHARE PURCHASE AGREEMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">#</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Initial Stated<br/> Value of<br/> Preferred<br/> Stock to be<br/> issued by<br/> installment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Warrants <br/> to be issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Closing Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Aggregate<br/> Purchase<br/> Price by<br/> installment <br/> (USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: left">Initial Closing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4iTj9VAWjDk" style="width: 12%; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">550,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zPZ5QF44Rev1" style="width: 12%; text-align: right" title="Warrants to be issued">3,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_980_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zkpQgXqhnfE6" style="width: 34%; text-align: justify" title="Closing Date">Initial Closing Date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--InitialClosingMember_zYRvyESsOx2k" title="Aggregate Purchase Price by installment">500,000</span> (“<span style="text-decoration: underline">Initial Closing Amount</span>”)</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_ze0GKt4hNGVb" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember_zDp3zXDMyAe6" title="Closing Date">On or before June 30, 2024</span> (the “<span style="text-decoration: underline">Second Closing Date</span>”)</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember_zsRa3qP1bQlc" title="Aggregate Purchase Price by installment">250,000</span> (“<span style="text-decoration: underline">Second Closing Amount</span>”)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zd0mJP5Wxs3" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zP5GR1TVJynl" style="text-align: right" title="Warrants to be issued">1,500,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zLFYCIFVN4Xd" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ThirdClosingMember_zwo1Owgr3nC8" title="Aggregate Purchase Price by installment">750,000</span> (“<span style="text-decoration: underline">Third Closing Amount</span>”)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Fourth Closing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4GJqbhmg143" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">1,100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zNQ6faPlPPoc" style="text-align: justify; padding-bottom: 1.5pt" title="Closing Date"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such date as is no later than 180 days (the “<span style="text-decoration: underline">Fourth Closing Date</span>”) after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act of 1933, as amended (the “<span style="text-decoration: underline">Securities Act</span>”), subject to any limitations pursuant to Rule 415</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--FourthClosingMember_zwpLTnlgsAOf" title="Aggregate Purchase Price by installment">1,000,000.00</span> (the “<span style="text-decoration: underline">Fourth Closing Amount</span>”)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zjx0hD9watfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">2,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zkWhOGUS9Qe7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants to be issued">4,800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zzhAAT6UaoMc" title="Aggregate Purchase Price by installment">2,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z6PxVyAGNGEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2024 (the “<span style="text-decoration: underline">Third Closing Date</span>”), the Company sold the Purchaser <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240628__20240628__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember_zekgyT5SiVW5" title="Number of shares sold">750</span> shares of Series B Preferred Stock (the “<span style="text-decoration: underline">Third Closing Shares</span>”) and (a) warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zbb7SUddgc1l" title="Number of warrants to purchase of common stock">1,000,000</span> shares of common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSkdcEJuFSfl" title="Exercise price per share">0.50</span> per share; and (b) warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_z5yf0ZfdwJvf" title="Number of warrants to purchase of common stock">500,000</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_z3GV6F6Lw6n" title="Exercise price per share">1.00</span> per share (collectively, (a) and (b), the “<span style="text-decoration: underline">Additional Warrants</span>”, and together with the Initial Warrants, the “<span style="text-decoration: underline">Warrants</span>”, and the shares of common stock issuable upon exercise of the Warrants, the “<span style="text-decoration: underline">Warrant Shares</span>”). The Additional Warrants are exercisable on or after October 4, 2024, and for five years thereafter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in the table above, the sale of an additional <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240628__20240628__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z01D3gdv9w0j" title="Number of shares sold">1,000</span> shares of Series B Preferred Stock in the Fourth Closing is subject to certain conditions to closing and is expected to occur within 180 days after the shares of common stock issuable upon conversion of the Series B Preferred Stock sold in the Initial Closing, Second Closing, Third Closing and Fourth Closing, have been registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 24, 2024, the Company entered into a Patent Purchase Agreement (the “<span style="text-decoration: underline">IP Purchase Agreement</span>”), with Intramont Technologies, Inc. (“<span style="text-decoration: underline">Intramont</span>”). Pursuant to the IP Purchase Agreement, we purchased certain patents and patent applications owned by Intramont, related to prevention of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “<span style="text-decoration: underline">Patents</span>”), in consideration for $<span id="xdx_901_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zQMv5POmj9ga" title="Consideration amount">20,000,000</span>, which is payable to Intramont by (a) the issuance of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zyfeGEO9v2se" title="Number of shares issued">980,000</span> shares of the Company’s then newly designated 6% Series C Convertible Preferred Stock (the “<span style="text-decoration: underline">Series C Preferred Stock</span>”), with a face value of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zahBniOK66Ik" title="Share price">20.00</span> per share, for a total value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zRU4g9aLYR8f" title="Number of shares issued, value">19,600,000</span>; and (b) $<span id="xdx_909_eus-gaap--Cash_iI_c20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbahV7ylADAb" title="Cash">400,000</span> in cash, <span id="xdx_902_ecustom--CumulativePreferredStockDescription_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zcRbn04yecm6" title="Cumulative preferred stock description">(i) with $200,000 payable on or before June 30, 2024, which was timely paid, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchased the Patents and assigned the Patents to its newly formed wholly-owned subsidiary, MangoRx IP Holdings, LLC, a Texas limited liability company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MangoRx Mexico </b>S.A. de C.V., a Mexican Stock Company, is <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxMexicoMember_zPhtJ4M5W1gk" title="Equity ownership percentage">98</span>% owned by Mangoceuticals, Inc. The entity was formed in September 2023 and had limited operations as of June 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MangoRx UK Limited</b>, a company incorporated under the laws of the United Kingdom, is <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember_zuWHwzejsAo5" title="Equity ownership percentage">100</span>% owned by Mangoceuticals, Inc. The entity was formed in October 2023 and has had limited operations as of June 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1250000 4.00 4350000 4765000 2000000 1.00 4000000 0.30 600000 4000000 1200000 1000000.0 280000 0.38 600000 600000 160000 4600000 42000 0.375 1500 1650000 3300000 1500000 500 500000 25000000 1000000 0.2149 214900 150000 150 100000 100 <p id="xdx_89C_ecustom--ScheduleOfSharePurchaseAgreementTableTextBlock_zbKV1LJeKsGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1 (the “<span style="text-decoration: underline">Amendment</span>”), which amended the SPA to, adjust the closings which were to take place under the SPA as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zHInElHXCBee">SCHEDULE OF SHARE PURCHASE AGREEMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">#</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Initial Stated<br/> Value of<br/> Preferred<br/> Stock to be<br/> issued by<br/> installment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Warrants <br/> to be issued</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Closing Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Aggregate<br/> Purchase<br/> Price by<br/> installment <br/> (USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: left">Initial Closing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4iTj9VAWjDk" style="width: 12%; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">550,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zPZ5QF44Rev1" style="width: 12%; text-align: right" title="Warrants to be issued">3,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_980_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zkpQgXqhnfE6" style="width: 34%; text-align: justify" title="Closing Date">Initial Closing Date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--InitialClosingMember_zYRvyESsOx2k" title="Aggregate Purchase Price by installment">500,000</span> (“<span style="text-decoration: underline">Initial Closing Amount</span>”)</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_ze0GKt4hNGVb" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember_zDp3zXDMyAe6" title="Closing Date">On or before June 30, 2024</span> (the “<span style="text-decoration: underline">Second Closing Date</span>”)</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember_zsRa3qP1bQlc" title="Aggregate Purchase Price by installment">250,000</span> (“<span style="text-decoration: underline">Second Closing Amount</span>”)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zd0mJP5Wxs3" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zP5GR1TVJynl" style="text-align: right" title="Warrants to be issued">1,500,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_98F_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zLFYCIFVN4Xd" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ThirdClosingMember_zwo1Owgr3nC8" title="Aggregate Purchase Price by installment">750,000</span> (“<span style="text-decoration: underline">Third Closing Amount</span>”)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Fourth Closing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4GJqbhmg143" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">1,100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zNQ6faPlPPoc" style="text-align: justify; padding-bottom: 1.5pt" title="Closing Date"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such date as is no later than 180 days (the “<span style="text-decoration: underline">Fourth Closing Date</span>”) after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act of 1933, as amended (the “<span style="text-decoration: underline">Securities Act</span>”), subject to any limitations pursuant to Rule 415</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--FourthClosingMember_zwpLTnlgsAOf" title="Aggregate Purchase Price by installment">1,000,000.00</span> (the “<span style="text-decoration: underline">Fourth Closing Amount</span>”)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zjx0hD9watfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">2,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zkWhOGUS9Qe7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants to be issued">4,800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zzhAAT6UaoMc" title="Aggregate Purchase Price by installment">2,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 550000 3300000 Initial Closing Date 500000 275000 On or before June 30, 2024 250000 825000 1500000 On or before June 30, 2024 750000 1100000 Such date as is no later than 180 days (the “Fourth Closing Date”) after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act of 1933, as amended (the “Securities Act”), subject to any limitations pursuant to Rule 415 1000000.00 2750000 4800000 2500000 750 1000000 0.50 500000 1.00 1000 20000000 980000 20.00 19600000 400000 (i) with $200,000 payable on or before June 30, 2024, which was timely paid, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024. 0.98 1 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zl8XyUpovy56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_823_zn3SEBK42IJi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXEbcslYcvD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zl32d042ETY6">Basis of Presentation</span> – </b>The condensed consolidated financial statements present the financial position, results of operations and cash flows of the Company in accordance with accounting principles generally accepted in the United States of America (“<span style="text-decoration: underline">US GAAP</span>”). All dollar amounts are rounded to the nearest thousand dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_840_ecustom--ReclassificationsPolicyTextBlock_zjr4q9mNDKD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span id="xdx_865_zdBeK0xxFZl7">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior period amounts have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zB6rOLGiKei5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zEw6EcPYNGld">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“<span style="text-decoration: underline">FDIC</span>”) insures the total cash balance up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20240630_ziq51elxLEGl" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20240630_zyKsrUL7XuMb" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_z7mWW1YtVNbf" title="Cash equivalents">no</span></span> cash equivalents at June 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zDFPOqXJeazg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z1h2lRXTSmU8">Principles of Consolidation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Mangoceuticals, Inc. and all wholly and majority-owned subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Wholly-owned subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">MangoRx UK Limited</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">MangoRx IP Holdings, LLC</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Majority-owned subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">The Company owns <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember__dei--LegalEntityAxis__custom--MangoRxIPHoldingsLLCMember_zdsWSRl2SJY7" title="Equity method investment ownership percentage.">98</span>% of MangoRx Mexico S.A. de C.V.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_843_ecustom--NonControllingInterestPolicyTextBlock_zsbKq1BQQ9f8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_864_zNZF1Y4yIfFk">Non-Controlling Interest</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company owns <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember__dei--LegalEntityAxis__custom--MangoRxIPHoldingsLLCMember_z9pHctDKvjSe" title="Equity method investment ownership percentage.">98</span>% of MangoRx Mexico S.A. de C.V.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVqw2wdluE6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zhzICgnYPO7b">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company operates as one segment, in which management uses one measure of profitability, and all of the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zkaMAuTnV6sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zHUnjjp6Y3B3">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes.  Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zfn8E7fM53ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zGLZ2bCqaVXf">Intangible Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets that have indefinite useful life are patents as of June 30,2024. The Company evaluates indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support indefinite useful lives. The value of indefinite-lived intangible assets is not amortized, but tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. As such, <span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_do_c20240101__20240630_zltg6wJe9Lx9" title="Impairment of indefinite lived intangible assets">no</span> impairment of indefinite-lived intangible assets was recognized for the six-month period ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyarZwhQbv1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_ziouExaj5K2b">Foreign Currency Translation and transaction</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company’s principal country of operations is United States. The financial position and results of its operations are determined using U.S. Dollars (“US$”), the local currency, as the functional currency. The Company’s financial statements are reported using the U.S. Dollars (“US$” or “$”). The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_898_ecustom--ScheduleOfForeignCurrencyTranslationAndTtransactionTableTextBlock_zg5VTWCn2s8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the financial statements:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTYtwfGqzX0l">SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, </b></span></td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_902_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember_zeqAv8DMJ5Y5" title="Period end spot rate">1</span>=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zMc5TK0P8E08" title="Period end spot rate">0.54</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_90B_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember_zY3v5PwHr9ik" title="Period end spot rate">1</span>=MX$<span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zRRGJBLj4rMa" title="Period end spot rate">0.58</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zovLJzfxo7Ng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zYlrRz7LXAg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZ41ynDBJ0Jk">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“<span style="text-decoration: underline">EPS</span>”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zE5flRDcEuke" title="Anti-dilutive securities">2,366,667</span> options, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqItzAAqU4I3" title="Anti-dilutive securities">6,185,000</span> warrants, and <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zP4GtaUuyuXb" title="Anti-dilutive securities">no</span> derivative securities outstanding as of June 30, 2024. There were <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zquvX41ByDS7" title="Anti-dilutive securities">2,650,000</span> options, <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVhT7XNmuxkd" title="Anti-dilutive securities">1,343,000</span> warrants, and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zKaUUrUCIBEb" title="Anti-dilutive securities">no</span> derivative securities outstanding as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zMsjLiDM2uV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zsgkYTHMAtV2">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zbzZuNU7kVOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zaBu8lrbmUj2">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, <i>Fair Value Measurement</i> (“<span style="text-decoration: underline">ASC 820</span>”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zx3AFx3qB645" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B3_z5FrhEQpZ9Jj" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRBtdGxFRIJl" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHTPciVrOEd8" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsDI6dhoE3ma" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Fair Value Measurements at June 30, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zce5kIcPkSjl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">490,243</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2731">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2732">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zOEZk8jG15C1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2735">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2736">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_z3R6N89rNmad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2739">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2740">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z12v7WIMughl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">490,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zy1gJAHvgxhb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zvwAVfBhoR7i" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziBtvB0VEpzj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zYiP1kC61Rm9" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2747">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl2748">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zkS1CEUuKyn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">739,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2751">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2752">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zXfcYArM3a5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2756">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zMzrekAhUFCf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2759">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2760">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z3jMdDtDt8h3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z43Bcgewsf98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zBh9o00rSBHf">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember_z6F2eM7WGvAh" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember_znOvkcal4Zlk" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zCkFHcHnAGz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zhw9mrDllY3">Concentration and Risks</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the six months ended June 30, 2024 and 2023, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z96j8QM8tIch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z8XllNGWdBWa">Black-Scholes Option Pricing Model</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy8VbjxZQ03k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zjeHVNMAxMl5">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--RelatedPartiesPolicyTextBlock_zDE1r5PUUiia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z92Oc4HS8mj1">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows subtopic 850-10 of FASB ASC 850, <i>Related Party</i> Disclosures for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 7 and 9 in the notes to consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZCD3T9r1Pq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zsnoNxUYfwf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - <i>Stock Compensation</i> (“<span style="text-decoration: underline">ASC 718</span>”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z8N3U6LoNL62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0lOMSGfd7C4">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 606. <i>Revenue from Contracts with Customer for recording and recognizing revenue from customers</i>. The Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“<span style="text-decoration: underline">Doctegrity</span>”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“<span style="text-decoration: underline">Contracted Pharmacy</span>”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_ztST2GqrRucf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zwAzd6kOjZg8">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“<span style="text-decoration: underline">FIFO</span>”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the six months ended June 30, 2024 and 2023, there were <span id="xdx_905_eus-gaap--InventoryWriteDown_do_c20240101__20240630_zanrqUr5jXL1" title="Inventory write-downs"><span id="xdx_901_eus-gaap--InventoryWriteDown_do_c20230101__20230630_zGTwBdlkNE5i" title="Inventory write-downs">no</span></span> inventory write-downs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zFhJNV7ha90k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zU2hXB870urk">Marketing and Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $<span id="xdx_903_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20240630_zXVzm9KPZ59f" title="Marketing and advertising expense">1,081,627</span> and $<span id="xdx_90F_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230630_zvrHYnG30O93" title="Marketing and advertising expense">912,997</span> towards marketing and advertising for the six months ended June 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z3BLhdCguNXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zy3mhuKXEKw8">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in Section 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the consolidated financial statements were issued (see Note 12).</span></p> <p id="xdx_857_z8tUkEdK0Kwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXEbcslYcvD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zl32d042ETY6">Basis of Presentation</span> – </b>The condensed consolidated financial statements present the financial position, results of operations and cash flows of the Company in accordance with accounting principles generally accepted in the United States of America (“<span style="text-decoration: underline">US GAAP</span>”). All dollar amounts are rounded to the nearest thousand dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_840_ecustom--ReclassificationsPolicyTextBlock_zjr4q9mNDKD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span id="xdx_865_zdBeK0xxFZl7">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior period amounts have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zB6rOLGiKei5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zEw6EcPYNGld">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (“<span style="text-decoration: underline">FDIC</span>”) insures the total cash balance up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20240630_ziq51elxLEGl" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20240630_zyKsrUL7XuMb" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_z7mWW1YtVNbf" title="Cash equivalents">no</span></span> cash equivalents at June 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 250000 0 0 <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zDFPOqXJeazg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z1h2lRXTSmU8">Principles of Consolidation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Mangoceuticals, Inc. and all wholly and majority-owned subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Wholly-owned subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">MangoRx UK Limited</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">MangoRx IP Holdings, LLC</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Majority-owned subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">The Company owns <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember__dei--LegalEntityAxis__custom--MangoRxIPHoldingsLLCMember_zdsWSRl2SJY7" title="Equity method investment ownership percentage.">98</span>% of MangoRx Mexico S.A. de C.V.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> 0.98 <p id="xdx_843_ecustom--NonControllingInterestPolicyTextBlock_zsbKq1BQQ9f8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_864_zNZF1Y4yIfFk">Non-Controlling Interest</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company owns <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MangoRxUKLimitedMember__dei--LegalEntityAxis__custom--MangoRxIPHoldingsLLCMember_z9pHctDKvjSe" title="Equity method investment ownership percentage.">98</span>% of MangoRx Mexico S.A. de C.V.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> 0.98 <p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVqw2wdluE6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zhzICgnYPO7b">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company operates as one segment, in which management uses one measure of profitability, and all of the Company’s assets are located in the United States of America. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not have separately reportable segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zkaMAuTnV6sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zHUnjjp6Y3B3">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes, as clarified by ASC 740-10, Accounting for Uncertainty in Income Taxes.  Under this method, deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of enacted tax laws. Deferred income tax provisions and benefits are based on changes to the assets or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which the Company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results or the ability to implement tax-planning strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more likely than not” criteria of ASC 740.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740-10 requires that the Company recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the “more-likely-than-not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zfn8E7fM53ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zGLZ2bCqaVXf">Intangible Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets that have indefinite useful life are patents as of June 30,2024. The Company evaluates indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support indefinite useful lives. The value of indefinite-lived intangible assets is not amortized, but tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. As such, <span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_do_c20240101__20240630_zltg6wJe9Lx9" title="Impairment of indefinite lived intangible assets">no</span> impairment of indefinite-lived intangible assets was recognized for the six-month period ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 0 <p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyarZwhQbv1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_ziouExaj5K2b">Foreign Currency Translation and transaction</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company’s principal country of operations is United States. The financial position and results of its operations are determined using U.S. Dollars (“US$”), the local currency, as the functional currency. The Company’s financial statements are reported using the U.S. Dollars (“US$” or “$”). The results of operations and the statements of cash flows denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation rate, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in statements of changes in shareholders’ equity. Gains and losses from foreign currency transactions are included in the Company’s statements of operations and comprehensive income (loss).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_898_ecustom--ScheduleOfForeignCurrencyTranslationAndTtransactionTableTextBlock_zg5VTWCn2s8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the financial statements:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTYtwfGqzX0l">SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, </b></span></td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_902_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember_zeqAv8DMJ5Y5" title="Period end spot rate">1</span>=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zMc5TK0P8E08" title="Period end spot rate">0.54</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_90B_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember_zY3v5PwHr9ik" title="Period end spot rate">1</span>=MX$<span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zRRGJBLj4rMa" title="Period end spot rate">0.58</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zovLJzfxo7Ng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfForeignCurrencyTranslationAndTtransactionTableTextBlock_zg5VTWCn2s8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table outlines the currency exchange rates that were used in preparing the financial statements:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zTYtwfGqzX0l">SCHEDULE OF FOREIGN CURRENCY TRANSLATION AND TRANSACTION</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, </b></span></td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Period-end spot rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_902_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember_zeqAv8DMJ5Y5" title="Period end spot rate">1</span>=MX$<span id="xdx_90A_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--PeriodEndSpotRateMember__srt--StatementGeographicalAxis__country--MX_zMc5TK0P8E08" title="Period end spot rate">0.54</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Average rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$<span id="xdx_90B_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember_zY3v5PwHr9ik" title="Period end spot rate">1</span>=MX$<span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20240630__us-gaap--AwardTypeAxis__custom--AverageRateMember__srt--StatementGeographicalAxis__country--MX_zRRGJBLj4rMa" title="Period end spot rate">0.58</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> </table> 1 0.54 1 0.58 <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zYlrRz7LXAg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZ41ynDBJ0Jk">Net Loss Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (“<span style="text-decoration: underline">EPS</span>”) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zE5flRDcEuke" title="Anti-dilutive securities">2,366,667</span> options, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqItzAAqU4I3" title="Anti-dilutive securities">6,185,000</span> warrants, and <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zP4GtaUuyuXb" title="Anti-dilutive securities">no</span> derivative securities outstanding as of June 30, 2024. There were <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zquvX41ByDS7" title="Anti-dilutive securities">2,650,000</span> options, <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVhT7XNmuxkd" title="Anti-dilutive securities">1,343,000</span> warrants, and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--DerivativeMember_zKaUUrUCIBEb" title="Anti-dilutive securities">no</span> derivative securities outstanding as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2366667 6185000 0 2650000 1343000 0 <p id="xdx_847_eus-gaap--UseOfEstimates_zMsjLiDM2uV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zsgkYTHMAtV2">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zbzZuNU7kVOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zaBu8lrbmUj2">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB ASC 820, <i>Fair Value Measurement</i> (“<span style="text-decoration: underline">ASC 820</span>”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zx3AFx3qB645" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B3_z5FrhEQpZ9Jj" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRBtdGxFRIJl" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHTPciVrOEd8" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsDI6dhoE3ma" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Fair Value Measurements at June 30, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zce5kIcPkSjl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">490,243</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2731">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2732">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zOEZk8jG15C1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2735">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2736">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_z3R6N89rNmad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2739">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2740">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z12v7WIMughl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">490,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zy1gJAHvgxhb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zvwAVfBhoR7i" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziBtvB0VEpzj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zYiP1kC61Rm9" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2747">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl2748">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zkS1CEUuKyn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">739,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2751">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2752">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zXfcYArM3a5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2756">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zMzrekAhUFCf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2759">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2760">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_z3jMdDtDt8h3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zx3AFx3qB645" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize our financial instruments measured at fair value as of June 30, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B3_z5FrhEQpZ9Jj" style="display: none">SCHEDULE OF FINANCIAL INSTRUMENTS MEASUREMENT AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRBtdGxFRIJl" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_494_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHTPciVrOEd8" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsDI6dhoE3ma" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Fair Value Measurements at June 30, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zce5kIcPkSjl" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">490,243</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2731">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2732">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zOEZk8jG15C1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2735">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2736">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_z3R6N89rNmad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2739">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2740">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_z12v7WIMughl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">490,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2743">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2744">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zy1gJAHvgxhb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zvwAVfBhoR7i" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziBtvB0VEpzj" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDzlJz_zYiP1kC61Rm9" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">739,006</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl2747">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl2748">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDzlJz_maFVNALzvC8_zkS1CEUuKyn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">739,006</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2751">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2752">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: center">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesFairValueDisclosure_iI_msFVNALzvC8_zXfcYArM3a5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2756">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzvC8_zMzrekAhUFCf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset (liability)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">739,006</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2759">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2760">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 490243 490243 490243 739006 739006 739006 <p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z43Bcgewsf98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zBh9o00rSBHf">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MinimumMember_z6F2eM7WGvAh" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240630__srt--RangeAxis__srt--MaximumMember_znOvkcal4Zlk" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P5Y <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zCkFHcHnAGz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zhw9mrDllY3">Concentration and Risks</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the six months ended June 30, 2024 and 2023, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z96j8QM8tIch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z8XllNGWdBWa">Black-Scholes Option Pricing Model</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zy8VbjxZQ03k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zjeHVNMAxMl5">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment’s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is also permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--RelatedPartiesPolicyTextBlock_zDE1r5PUUiia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z92Oc4HS8mj1">Related Parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows subtopic 850-10 of FASB ASC 850, <i>Related Party</i> Disclosures for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Material related party transactions have been identified in Notes 3, 7 and 9 in the notes to consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZCD3T9r1Pq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zsnoNxUYfwf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs to employees under FASB ASC 718 Compensation - <i>Stock Compensation</i> (“<span style="text-decoration: underline">ASC 718</span>”). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option and warrant grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z8N3U6LoNL62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z0lOMSGfd7C4">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 606. <i>Revenue from Contracts with Customer for recording and recognizing revenue from customers</i>. The Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform. Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer obtains control of the products and services upon the Company’s completion of its performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (“<span style="text-decoration: underline">Doctegrity</span>”) to provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (“<span style="text-decoration: underline">Contracted Pharmacy</span>”), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer’s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_ztST2GqrRucf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zwAzd6kOjZg8">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value with cost being determined on a first-in, first-out (“<span style="text-decoration: underline">FIFO</span>”) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the six months ended June 30, 2024 and 2023, there were <span id="xdx_905_eus-gaap--InventoryWriteDown_do_c20240101__20240630_zanrqUr5jXL1" title="Inventory write-downs"><span id="xdx_901_eus-gaap--InventoryWriteDown_do_c20230101__20230630_zGTwBdlkNE5i" title="Inventory write-downs">no</span></span> inventory write-downs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zFhJNV7ha90k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zU2hXB870urk">Marketing and Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged $<span id="xdx_903_eus-gaap--MarketingAndAdvertisingExpense_c20240101__20240630_zXVzm9KPZ59f" title="Marketing and advertising expense">1,081,627</span> and $<span id="xdx_90F_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230630_zvrHYnG30O93" title="Marketing and advertising expense">912,997</span> towards marketing and advertising for the six months ended June 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1081627 912997 <p id="xdx_84B_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z3BLhdCguNXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zy3mhuKXEKw8">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in Section 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the consolidated financial statements were issued (see Note 12).</span></p> <p id="xdx_807_ecustom--PrepaidExpensesRelatedPartiesTextBlock_zGHP8nMNRTLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_82C_zRoKsZ0YxsB5">PREPAID EXPENSES-RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2024 and the year ended December 31, 2023, and in association with the Master Services Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy as a retainer to be credited towards future product sales. As of June 30, 2024 and December 31, 2023, the balance was $<span id="xdx_90F_ecustom--PrepaidExpensesRelatedParty_iI_c20240630_z9aMqUqUCnak" title="Prepaid expenses related party">13,299</span> and $<span id="xdx_90A_ecustom--PrepaidExpensesRelatedParty_iI_c20231231_zqxQhvdtZxfk" title="Prepaid expenses related party">60,953</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13299 60953 <p id="xdx_80F_ecustom--DepositDisclosuresTextBlock_zpffHVDgTBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_824_zEW7w3bXVWtd">DEPOSITS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $<span id="xdx_901_eus-gaap--DepositsAssets_iI_c20240630_zCWZ2D9TuTtg" title="Deposit">16,942</span>. As of June 30, 2024 and December 31, 2023, the balance was $<span id="xdx_902_eus-gaap--OtherAssets_iI_c20240630_ziybpyhkvU1c" title="Balance amount"><span id="xdx_900_eus-gaap--OtherAssets_iI_c20231231_zxwUDD1r6qpg" title="Balance amount">16,942</span></span> for each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 16942 16942 16942 <p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zXqznHheIi62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_828_zPK5TLbsIrg4">INVENTORY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2024 and the year ended December 31, 2023, the Company purchased inventories related to promotional merchandise intended to be sold online. As of June 30, 2024 and December 31, 2023, the inventory balance was $<span id="xdx_90D_eus-gaap--InventoryNet_iI_c20240630_zfrSN3yntFm5" title="Inventory">14,019</span> and $<span id="xdx_90F_eus-gaap--InventoryNet_iI_c20231231_zzxJuPGndOzk" title="Inventory">18,501</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 14019 18501 <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z7pj693oTvI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_824_zA89RGWmSdba">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2024 and 2023, the Company acquired computers and office equipment totaling $<span id="xdx_90C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_dxL_c20240101__20240630_zpAcO3VPS6c" title="Acquired computers and office equipment::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2816">0</span></span> and $<span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20230101__20230630_zDzZSq2oxWWh" title="Acquired computers and office equipment">3,519</span>, respectively. Depreciation for the six months ended June 30, 2024 and 2023 was $<span id="xdx_90B_eus-gaap--DepreciationDepletionAndAmortization_c20240101__20240630_zU1ejrlF3JR8" title="Depreciation">1,749</span> and $<span id="xdx_904_eus-gaap--DepreciationDepletionAndAmortization_c20230101__20230630_zOwZxQAo4ryd" title="Depreciation">6,082</span>, respectively. On May 15, 2024, the Company disposed of $<span id="xdx_906_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_c20240515_zzZuf8t6KyOj" title="Disposed equipment">119,819</span> of equipment to Epiq Scripts, a related party, in an arm’s length transaction. The equipment was sold for $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfMachineryAndEquipment_c20240101__20240630_zTKShNucqVE2" title="Equipment was sold">65,000</span>, realizing a loss on sale of assets of $<span id="xdx_90E_eus-gaap--GainLossOnSaleOfOtherAssets_c20240101__20240630_zjTiy8kDzhI8" title="Realizing a loss on sale of assets">18,837</span>. Total net property, plant and equipment was $<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240630_zbiYNwVKDnt6" title="Total net property plant and equipment">3,313</span> and $<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_zD9LtMxlR2Bl" title="Total net property plant and equipment">96,129</span>, as of June 30, 2024 and December 31, 2023, respectively. The below schedule shows property, plant and equipment as of:</span></p> <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z4G1R1wlExUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8BA_zFFEuaTU5hcj" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_499_20240630_z5JshFnwJEAf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">June 30, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_493_20231231_zj8f0vhLqiDk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_maPPAENz1or_zjAcKoMIBE5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">     5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENz1or_z9WBV8DEOzxk" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,819</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz1or_zK0XJVzX4fqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Less accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,749</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,752</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--DisposedEquipmentPropertyPlantAndEquipment_iNI_di_msPPAENz1or_zwYoz0pcnFtk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Disposed equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,819</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz1or_zb3kybMKZf8d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">96,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zhevVvfxil7b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3519 1749 6082 119819 65000 18837 3313 96129 <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z4G1R1wlExUi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_8BA_zFFEuaTU5hcj" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_499_20240630_z5JshFnwJEAf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">June 30, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_493_20231231_zj8f0vhLqiDk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_maPPAENz1or_zjAcKoMIBE5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Computers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5,062</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">     5,062</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--MachineryAndEquipmentGross_iI_maPPAENz1or_z9WBV8DEOzxk" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,819</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz1or_zK0XJVzX4fqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Less accumulated depreciation:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,749</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28,752</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--DisposedEquipmentPropertyPlantAndEquipment_iNI_di_msPPAENz1or_zwYoz0pcnFtk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Disposed equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,819</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz1or_zb3kybMKZf8d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">96,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5062 5062 119819 119819 1749 28752 119819 -119819 3313 96129 <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaKLB2ZyJ47g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82A_zK9T74dtmvVg">LOANS FROM RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211209__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zyJSYWu8i8o1" title="Related party advances received">39,200</span> and $<span id="xdx_900_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220317__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z70VQS2yQKC1" title="Related party advances received">50,000</span>, respectively, for a total of $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zjOfhSfZAPv" title="Related party advances received">89,200</span> from its previous majority shareholder, American International Holdings Corp (“<span style="text-decoration: underline">AMIH</span>”), in order to cover various general and administrative expenses. The advances bear no interest and are due on demand upon the Company’s ability to repay the advances from either future revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (“<span style="text-decoration: underline">Cohen Enterprises</span>”), an entity owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman of the Board of Directors, entered into and closed a Stock Purchase Agreement (the “<span style="text-decoration: underline">SPA</span>”) for the purchase of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_znwOjB4sR6P9" title="Issuance of shares">8,000,000</span> shares of the outstanding common stock of the Company which were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_z7H9pqx0JVdl" title="Equity ownership interest">80</span>% of the Company’s then outstanding shares of common stock, in consideration for $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zlUGYoTLZPF" title="Proceeds from issuance of common stock">90,000</span>. Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zG4XevTRckK5" title="Repayments of related party debt">89,200</span> advanced from AMIH to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2022, the Company received an advance of $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211209__20211210__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZipDoctorIncMember_zkpFyOAhWVPj" title="Related party advances received">25,000</span> from Cohen Enterprises in order to cover various general and administrative expenses. The Company repaid Cohen Enterprises $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zUqqPFM4K6Jl" title="Repayments of related party debt">25,000</span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_906_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_z5r2D6vePiQa" title="Repayment of related party debt">89,200</span> as of December 31, 2022. This amount was paid in full on April 4, 2023 and the amount owed to Cohen Enterprises was $<span id="xdx_907_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zJ3outDz6Ph8" title="Proceeds from related party"><span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zA226Q0r6yul" title="Proceeds from related party">0</span></span> as of June 30, 2024 and December 31, 2023. Previously recorded imputed interest equal to eight percent (<span id="xdx_90F_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20240101__20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zHlUsaZ5REzj" title="Imputed interest percentage">8</span>%) per annum, or a total of $<span id="xdx_902_eus-gaap--PaymentsForAdvanceToAffiliate_c20240101__20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zvK9CXLD5htb" title="Related party transaction purchases">8,232</span> against the related party advances, was canceled and reversed for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2024, the Company borrowed $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_c20240301__dei--LegalEntityAxis__custom--RoninEquityPartnersMember_zs6FaGvRYlBe" title="Borrow amount">37,500</span> from Ronin Equity Partners, which is owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman of the Board of Directors. The amount borrowed is payable on demand and does not accrue interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2024, the Company borrowed $<span id="xdx_903_eus-gaap--LongTermDebt_iI_c20240318__dei--LegalEntityAxis__custom--CohenEnterprisesIncMember_zsIniYRJ6jze" title="Borrow amount">50,000</span> from Cohen Enterprises which is owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman of the Board of Directors. The amount borrowed is payable on demand and does not accrue interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2024, the Company borrowed $<span id="xdx_90B_eus-gaap--LongTermDebt_iI_c20240401__dei--LegalEntityAxis__custom--CohenEnterprisesIncMember_zx7x9NhdqhM" title="Borrow amount">100,000</span> from Cohen Enterprises, which is owned and controlled by Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman of the Board of Directors. The amount borrowed is payable on demand and does not accrue interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For additional information on related party prepaid expenses see Note 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 39200 50000 89200 8000000 0.80 90000 89200 25000 25000 89200 0 0 0.08 8232 37500 50000 100000 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_z1LsgnxfvBu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_825_zsIhQ1HplBJ8">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_zGe3BTl8vvh6" title="Debt instrument face amount">78,260</span>. The note bears no interest and was due in three payments of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230301_zn4Efn8ZPtw4" title="Debt instrument periodic payment">5,000</span> each January 1, 2023 through March 1, 2023, a $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_zDs8ktodBUac" title="Debt instrument periodic payment">31,630</span> payment on April 1, 2023 and a final payment on May 1, 2023 for the outstanding balance. The January 1 and March 1, 2023 payments were timely made and on March 23, 2023, the Company elected to pay off the remaining balance of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20230323__20230323_ztSW4bG2waRj" title="Repayments of notes payable">63,260</span>. The outstanding balance as of June 30, 2024 and December 31, 2023 was $<span id="xdx_907_eus-gaap--NotesPayable_iI_dxL_c20240630_zjpYxto094W5" title="Notes payable::XDX::-"><span id="xdx_909_eus-gaap--NotesPayable_iI_dxL_c20231231_z44TAvbu3kig" title="Notes payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2897"><span style="-sec-ix-hidden: xdx2ixbrl2899">0</span></span></span></span>. See Note 6 for further details regarding the subsequent sale of this equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 78260 5000 31630 63260 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zL8utiI9rTN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82B_zC4ox76TQqag">CAPITAL STOCK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue up to <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_zbKo5HLHKe4h" title="Preferred stock, shares authorized">10,000,000</span> shares of “<span style="text-decoration: underline">blank check</span>” preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20240630_zPW7v71GJTv6" title="Preferred stock par value">0.0001</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Convertible Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024 and amended on June 27, 2024, the Company designated <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmBiLQi3zWtg" title="Preferred stock, shares authorized">6,000</span> shares of the Company’s Series B Convertible Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z7k4vsGXCEHa" title="PreferredStock, par value">0.0001</span> per share (the “<span style="text-decoration: underline">Series B Preferred Stock</span>”). Each Series B Preferred Stock share has a stated value equal to $<span id="xdx_906_ecustom--PreferredStockStatedValue_iI_pid_c20240328__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvD8rtsJfP3j" title="Preferred stock stated value">1,100</span>, subject to increase under the terms of the designation (the “<span style="text-decoration: underline">Stated Value</span>”). As of June 30, 2024 and December 31, 2023 there were <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zG8USd8OFvY" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zpw7n0tANJ35" title="Preferred stock, shares outstanding">2,145</span></span> and -<span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zR6jppd6Totg" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zArqsFM0NY5l" title="Preferred stock, shares outstanding">0</span></span>- shares of Series B Preferred Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2024, we agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024, with an institutional accredited investor, pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2OoJfjiVqUc" title="Number of shares issued">1,500</span> shares of Series B Preferred Stock for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuQGaSfY2OK1" title="Number of shares issued, value">1,650,000</span>, and warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zluXqsnJC5Ui" title="Warrants to purchase common stock">3,300,000</span> shares of common stock for an aggregate purchase price of $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueWarrants_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7byD2S9q4D7" title="Purchase price of warrants">1,500,000</span>. On the Initial Closing Date, the Company sold the Purchaser <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240405__20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHBgtyg6eSA7" title="Number of shares sold">500</span> shares of Series B Preferred Stock and the Initial Warrants, for an aggregate of $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240405__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ80Z5AWfxe3" title="Aggregate amount for warrant">500,000</span>. The Initial Warrants can be exercised separately from the Series B Preferred Stock. Thus, the warrants are a freestanding financial instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2024, the Company partially closed a planned second closing under the SPA whereby the Purchaser paid $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zltv76sPQt6c" title="Shares paid amount">150,000</span> to the Company in consideration for <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240426__20240426__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1fXQKz44oK7" title="Number of shares sold">150</span> shares of Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2024, the Company closed the remaining portion of the Second Closing whereby the Purchaser paid $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240517__20240517__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6q4NUChFSh3" title="Sale of stock value">100,000</span> to the Company in consideration for <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240517__20240517__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHih5QVBFTei" title="Number of shares sold">100</span> shares of Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfSharesPurchaseAgreementTableTextBlock_zJEn1AdNZ5l1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1, which amended the SPA to, adjust the closings which were to take place under the SPA as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zFYw4ERUi8J2" style="display: none">SCHEDULE OF SHARE PURCHASE AGREEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">#</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Initial Stated<br/> Value of<br/> Preferred<br/> Stock to be<br/> issued by<br/> installment</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Warrants<br/> to be issued</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Closing Date</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Aggregate<br/> Purchase<br/> Price by<br/> installment<br/> (USD)</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: left">Initial Closing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zyfzRbK2slHi" style="width: 12%; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">550,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zzmtcwfSMy55" style="width: 12%; text-align: right" title="Warrants to be issued">3,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zf5MmTqv8wx4" style="width: 38%; text-align: justify" title="Closing Date">Initial Closing Date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--InitialClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zEdR7zuK4Bbi" title="Aggregate Purchase Price by installment">500,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zqLiMwYXQVG" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td id="xdx_988_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z6JllAXYxKha" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zcGP3rqTJiJ3" title="Aggregate Purchase Price by installment">250,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zJviH2RByN28" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zylka7ttZUl2" style="text-align: right" title="Warrants to be issued">1,500,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_989_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zQDhkLl0Mb5h" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z6i1mL6NejZ8" title="Aggregate Purchase Price by installment">750,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Fourth Closing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zPCUssFGmN8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">1,100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zzVb1vLWbP2j" style="text-align: justify; padding-bottom: 1.5pt" title="Closing Date">Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--FourthClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zJE3iLFtnc38" title="Aggregate Purchase Price by installment">1,000,000.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z2CnNNqY51Lj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">2,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zCkFgasphune" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants to be issued">4,800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zlQ6Iz2F5ZC" title="Aggregate Purchase Price by installment">2,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z2sA1bJp8eu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2024, the Company sold the Purchaser <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240628__20240628__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember_zpenCQDF3fnd" title="Number of shares sold">750</span> shares of Series B Preferred Stock and (a) warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_znhBtUi3KIN8" title="Number of warrants to purchase of common stock">1,000,000</span> shares of common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zeoyYWVkRqUj" title="Exercise price per share">0.50</span> per share; and (b) warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240628__us-gaap--AwardTypeAxis__custom--ThridClosingDateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zWo6fwVh1OR2" title="Number of warrants to purchase of common stock">500,000</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zcx3AQiRCQt5" title="Exercise price per share">1.00</span> per share. The warrants can be exercised separately from the Series B Preferred Stock. Therefore, the warrants are a freestanding financial instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in the table above, the sale of an additional <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240628__20240628__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqgHYgsBkg1k" title="Number of shares sold">1,000</span> shares of Series B Preferred Stock in the Fourth Closing is subject to certain conditions to closing and is expected to occur within 180 days after the shares of common stock issuable upon conversion of the Series B Preferred Stock sold in the Initial Closing, Second Closing, Third Closing and Fourth Closing, have been registered under the Securities Act</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2024, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240521__20240521__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQSzqXTeTo" title="Shares new issues">50</span> shares of Series B Preferred Stock (with an aggregate stated value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240521__20240521__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCm1UIHnsS3d" title="Aggregate stated value">55,000</span>) were converted by the holder into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240521__20240521__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZ5EfJ3odqD3" title="Number of converted shares">270,936</span> shares of common stock at a conversion price of $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240521__20240521__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziLrLyaah8F2" title="Conversion price">0.203</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2024, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240522__20240522__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJNO5TGCA3t3" title="Shares new issues">155</span> shares of Series B Preferred Stock (with an aggregate stated value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240522__20240522__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zv4nvY5OOqH5" title="Aggregate stated value">170,500</span>) were converted into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240522__20240522__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zH50aj7tB6b8" title="Number of converted shares">839,901</span> shares of common stock at a conversion price of $<span id="xdx_906_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240522__20240522__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKNMRVhwcmlk" title="Conversion price">0.203</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2024, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240524__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXaHVeB3uMbg" title="Shares new issues">150</span> shares of Series B Preferred Stock (with an aggregate stated value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240524__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCqjzWJAzQIl" title="Aggregate stated value">165,000</span>) were converted into <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240524__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPoxuS9MkGak" title="Number of converted shares">812,807</span> shares of common stock at a conversion price of $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240524__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTbgU9ytR3Zk" title="Conversion price">0.203</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6% Series C Convertible Cumulative Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 18, 2024, the Company designated <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240418__20240418__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zQbWbcsB71N9" title="Shares new issues">6,250,000</span> shares of a new series of preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240418__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zAGhtBaYTJel" title="Preferred stock, par value">0.0001</span> per share, the Company’s “6% Series C Convertible Cumulative Preferred Stock” (the “<span style="text-decoration: underline">Series C Preferred Stock</span>”). As of June 30, 2024 and December 31, 2023, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20240630__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zp2ltIvBSAx7" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240630__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zc0ldkBrdpzk" title="Preferred stock, shares outstanding">980,000</span></span> and -<span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zvKccsS81hn" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_z8ePx00ANMY6" title="Preferred stock, shares outstanding">0</span></span>- shares of Series C Preferred Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 24, 2024, the Company entered into a Patent Purchase Agreement, with Intramont Technologies, Inc. Pursuant to the IP Purchase Agreement, the Company purchased certain patents and patent applications owned by Intramont, related to prevention of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV), in consideration for $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zNFaN9NI4Uxh" title="Consideration amount">20,000,000</span>, which is payable to Intramont by (a) the issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zZ2Nfyeb84qf" title="Number of shares issued">980,000</span> shares of Series C Preferred Stock, with a face value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zfhV2TiSNIY2" title="Share price">20.00</span> per share, for a total value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zLiXYlkka3s6" title="Number of shares issued, value">19,600,000</span>; and (b) $<span id="xdx_90E_eus-gaap--Cash_iI_c20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zBDGw7UM6wxa" title="Cash">400,000</span> in cash, <span id="xdx_90A_ecustom--CumulativePreferredStockDescription_c20240424__20240424__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SixPercentageSeriesCConvertibleCumulativePreferredStockMember_zJzwQIkpFyNh" title="Cumulative preferred stock description">(i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zgxwOQytkvCk" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zHcE2aj9HnKi" title="Common stock, shares authorized">200,000,000</span></span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zCWhrby1wS03" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zImduSouYkFf" title="Common stock, par value">0.0001</span></span> per share, of which <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20240630_zJ54dYe9qore" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240630_zuVZ2cHgDiE" title="Common stock, shares outstanding">29,135,451</span></span> shares were issued and outstanding at June 30, 2024, and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zFraWyo9cN69" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zjc3cqsH4EZi" title="Common stock, shares outstanding">21,419,500</span></span> shares were issued and outstanding at December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (“<span style="text-decoration: underline">DojoLabs</span>”), to provide various strategic marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEcqVaYaRrl5" title="Shares issued">100,000</span> in cash and issued DojoLabs <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z19wsQgtKaz6" title="Shares issued">50,000</span> shares of restricted common stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbKym6MtR3Kl" title="Share price">1.00</span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhG2qxg5twog" title="Shares issued value">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (“<span style="text-decoration: underline">Bethor</span>”), to provide strategic advisory services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Bethor <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zz9kIWjAWbhe" title="Shares issued">250,000</span> shares of restricted common stock with registration rights. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlrSDz42mkK" title="Share price">1.00</span> per share for a total of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWRVd0qC015e" title="Shares issued value">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2023, the Company established an advisory board (the “<span style="text-decoration: underline">Advisory Board</span>”) and approved and adopted a charter (the “<span style="text-decoration: underline">Advisory Board Charter</span>”) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory Board is to assist the Board of Directors in its general oversight of the Company’s development of new business ventures and strategic planning.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (“<span style="text-decoration: underline">Dr. Rudman</span>”) and Mr. Jarrett Boon (“<span style="text-decoration: underline">Mr. Boon</span>”), both of whom are independent, non-Board members and non-Company employees, to the Advisory Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with Dr. Rudman’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “<span style="text-decoration: underline">Dr. Rudman Consulting Agreement</span>”), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zW24AstjhqPa" title="Shares issued">25,000</span> shares of the Company’s restricted common stock, pay Dr. Rudman $<span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRrwPtlEGjQ1" title="Compensation expense">2,000</span> per month in cash, and reimburse Dr. Rudman for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeIP2r9NqMJl" title="Share price">1.00</span> per share for a total of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAtoHsrwe6o9" title="Shares issued value">25,000</span>. The term of the Dr. Rudman Consulting Agreement was for a period of one (1) year and was not renewed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with Mr. Boon’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “<span style="text-decoration: underline">Mr. Boon Consulting Agreement</span>”), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwj99pmurBR3" title="Shares issued">25,000</span> shares of the Company’s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9z7gF1Syumh" title="Share price">1.00</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPsZxBaAy3kf" title="Shares issued value">25,000</span>. The term of the Mr. Boon Consulting Agreement was for a period of one (1) year and was not renewed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3) Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, <span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z52ZmnIVZob4" title="Settlement description">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Mr. Haroon and Ms. Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Mr. Helfrich and Mr. Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</span> Any shares not vested by the eighteen-month anniversary of the applicable agreement are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zxeVm2nhNTCf" title="Share price">1.00</span> per share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zupi3yZ1X6y8" title="Shares issued value">350,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2023, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKmgMV0d7Vwd" title="Number of shares sold">1,250,000</span> shares of its common stock at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq21sVi6Jlvg" title="Share price">4.00</span> per share to investors in connection with its IPO for gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy40bkMiYda4" title="Gross proceeds">5,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 24, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z5GB092auzce" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zsfrCmr8hOAa" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230424__20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zUeKa1cyVN73" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zz0MvZkLUD18" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zjIO65DMz7Pb" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zGyvJxLpYF04" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zovlMWn0Mp1g" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zTRnVQU8PZN1" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zR2hQgntRSV2" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zEtF7asHxCrj" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zrvZzfGcmaW8" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zDtxtU5FfGp3" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zNlFiACVNZL7" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zqrhPT0tMjB1" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zbWR0z6E5twl" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 26, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zBNZDS4wgCif" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zuuhUscjGiPf" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230426__20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zO83KgWzZ7Mk" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zy4oWN2rWes3" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zgQqt08kVpmf" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zUIeLUoujtGd" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the “<span style="text-decoration: underline">Employment Agreement</span>”). The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for Mrs. Hammer to receive an annual salary of $<span id="xdx_906_eus-gaap--PaymentsToEmployees_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_z8jdDHPmqH46">150,000</span> per year. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_z0DVcMgWbXn1" title="Stock options description">The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_uUSDPShares_c20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zscoL6ViYVD">1.00</span> per share, with options to purchase <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zED6nrxVSgKa">50,000</span> shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and Mrs. Hammer.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (“<span style="text-decoration: underline">Redlime</span>”) to provide software development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Redlime $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4KKSKipkYXd" title="Consideration paid">300,000</span> in cash and issue Redlime <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKrXkraqZ5Pd" title="Shares issued shares">180,000</span> shares of restricted common stock. The shares were valued at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRiFer5TKF01" title="Share price">1.00</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkISrz4zrxNf" title="Shares issued value">180,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (“<span style="text-decoration: underline">Mr. Andrew</span>”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Mr. Andrew’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “<span style="text-decoration: underline">Mr. Andrew Consulting Agreement</span>”), dated effective May 25, 2023, with Mr. Andrew, whereby the Company agreed to issue Mr. Andrew <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zGvGHbdkEjBl" title="Shares issued">50,000</span> shares of the Company’s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z9xJncEUzHZ9" title="Share price">1.10</span> per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zXnvgeEvgXe4" title="Shares issued value">55,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2023, we entered into a Consulting Agreement with Major Dodge (“<span style="text-decoration: underline">Major</span>”), to provide acting and production related services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Major <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zNs4SsBrnq2c" title="Shares issued">20,000</span> shares of restricted common stock under the 2022 Plan. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zscX46sVV0Oa" title="Share price">1.10</span> per share for a total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z0vUbNusVrFl" title="Shares issued value">22,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (“<span style="text-decoration: underline">New To The Street</span>”), to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for three months. In consideration for agreeing to provide the services under the agreement, the Company issued New To The Street <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9UG58nvvQr3" title="Shares issued">50,000</span> shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRMKjZXQyBuf" title="Debt instrument periodic payment">5,000</span>. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znu1KQBy8e4k" title="Share price">1.10</span> per share for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zn4h9L80ZZFb" title="Shares issued value">55,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zdl7RyG1apt8" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zLPusjt0CFo1" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230605__20230605__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zLxCba4tLI4f" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 6, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zvS2VgOS6Y28" title="Warrants to purchase">150,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z4xksfdLmbd" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zSSklQcrtnYk" title="Consideration paid">150,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 7, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zo6Zt1XnK62h" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zUE7XSdg1jP5" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230607__20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zJD4Mfxsza5i" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 8, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zx2dAQbhfKK2" title="Warrants to purchase">24,500</span> shares of common stock with an exercise price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zR4goZUrlJHd" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230608__20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zMfNfeVNRcp4" title="Consideration paid">24,500</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 21, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_z8n3Clhzs6Q" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zxWuKlVxSjWe" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230621__20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zarU1fy18Glh" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zSti72FKrrv3" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zFM3jMtBw32k" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zwcKLJlLiGn3" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2023, a warrant holder exercised private placement warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_z1ncOAWpCwE7" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zh7dtZBAVZP7" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230627__20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zCDLz6iiYHka" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (“<span style="text-decoration: underline">Greentree</span>” and the “<span style="text-decoration: underline">Service Agreement</span>”). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company agreed to issue Greentree <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_z9pW8Iia5BZ5" title="Shares issued in consideration">75,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement, and to pay Greentree $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zmg11D4Dn4tb" title="Paid in cash">40,000</span> in cash, payable as follows: <span id="xdx_90B_eus-gaap--CommonStockConversionFeatures_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zb1rvM1q5iR4" title="Settlement description">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024</span>. We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree’s activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20240630__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zLPopNKymVe1" title="Share price">1.13</span> per share for a total of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zSceX65EPlp4" title="Shares issued value">84,750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2023, the Company executed a Summary of Terms and Conditions (“<span style="text-decoration: underline">Consulting Agreement</span>”) with Gene Johnston (“<span style="text-decoration: underline">Johnston</span>”) continuing his appointment as the Company’s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the Consulting Agreement, the Company issued Johnston <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zp9S2JqvrC03" title="Stock issued during period, shares">50,000</span> shares of the Company’s common stock and agreed to pay $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuPUWoFREFE8" title="Stock issued during period, value">2,000</span> per month. The Consulting Shares were issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (“<span style="text-decoration: underline">Luca</span>”), to provide certain management and consulting services to the Company during the term of the agreement, which was for three months. In consideration for agreeing to provide the services under the agreement, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zo3mPqp7Dkwe" title="Stock issued during period, shares">200,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement and to pay Luca $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zzz1kMZNJYgf" title="Stock value paid in cash">15,000</span> in cash, payable as follows: <span id="xdx_90C_eus-gaap--CommonStockConversionFeatures_c20231010__20231010__dei--LegalEntityAxis__custom--LucaConsultingLlcMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zriXaIwq0sd8" title="Settlement description">(a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement.</span> The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zxjwhYG1E7Zj" title="Stock issued price per share">0.63</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zNxQ5SbVFA8h" title="Stock issued during period, value">126,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2023, we entered into an Influencer Agreement with Jason Szkup (“<span style="text-decoration: underline">Scoop</span>”) to promote its products or services through social media platforms and other online channels, In consideration for agreeing to provide the services under the agreement, the Company agreed to pay Scoop $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ze9iNUg8JpAd" title="Shares issued">10,000</span> in cash and issue <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyPjJhuMRRz" title="Shares issued">30,000</span> shares. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztYj5pDZWXj8" title="Share price">0.58</span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231101__20231101__dei--LegalEntityAxis__custom--JasonSzkupMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOtH5lvDyiEa" title="Shares issued value">17,400</span>. The Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2023, the Board of Directors appointed Dr. Douglas Christianson, ND (“<span style="text-decoration: underline">Dr. Christianson</span>”), an independent, non-Board member and non-Company employee, to the Advisory Board. In connection with Dr. Christianson’s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the “<span style="text-decoration: underline">Dr. Christianson Consulting Agreement</span>”), with Dr. Christianson, whereby the Company agreed to issue Dr. Christianson <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231101__20231101__srt--TitleOfIndividualAxis__custom--DrDouglasChristiansonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkOq4sIeFeZc" title="Shares issued">50,000</span> shares. The Shares shall be issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The Company will reimburse Dr. Christianson for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company’s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231101__srt--TitleOfIndividualAxis__custom--DrDouglasChristiansonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOettiX3kVc7" title="Share price">0.58</span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231101__20231101__srt--TitleOfIndividualAxis__custom--DrDouglasChristiansonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zltQWKlsru7h" title="Shares issued value">29,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2023, we renewed a Consulting Agreement with PHX Global, LLC (“<span style="text-decoration: underline">PHX</span>”). Pursuant to the Consulting Agreement, PHX agreed to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231115__20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIHBvQlqvL6d" title="Shares issued">200,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zl2lgLJXHG3e" title="Share price">0.47</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231115__20231115__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQ1DPB6v1Jal" title="Shares issued value">94,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2023, the Company entered into a Marketing Agreement with Marius Pharmaceuticals (“<span style="text-decoration: underline">Marius</span>”) to market and sell KYZATREX®, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, ‘PRIME’ by MangoRx (the “<span style="text-decoration: underline">Permitted Purpose</span>”). During the Term, Marius granted to the Company a non-exclusive, non-transferable, royalty-free license to use the Marius Marks in the United States (the “<span style="text-decoration: underline">Territory</span>”) for the sole purpose of the Permitted Purpose. The term of the initial agreement is for two years, automatically renewable for successive one-year terms, subject to certain performance targets as agreed upon each year. As consideration for the license the Company issued Marius one hundred thousand (<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231211__20231211__dei--LegalEntityAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUlsehBk13Gh" title="Shares issued">100,000</span>) shares of the Company’s common stock (the “<span style="text-decoration: underline">Marius Shares</span>”). The Marius Shares were issued to Marius upon signing of the Agreement and were fully earned upon issuance. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20231211__dei--LegalEntityAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRFikhd5MDE4" title="Share price">0.58</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231211__20231211__dei--LegalEntityAxis__custom--MariusPharmaceuticalsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zerQ1LpE9GQ2" title="Shares issued value">58,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2023, the Company sold <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz2yK1xFEq2c" title="Number of shares sold">4,000,000</span> shares of its common stock at a price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfXm1Gw3KmP8" title="Share price">0.30</span> per share to investors in connection with a follow-on offering for gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMwQmJTBIX7" title="Gross proceeds">1,200,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 2, 2024, we entered into a Consulting Agreement with G&amp;P General Consulting (“<span style="text-decoration: underline">G&amp;P</span>”), Pursuant to the Consulting Agreement, G&amp;P agreed to provide consulting and general business advisory services as it relates to the expansion of the Company’s products into additional international territory’s, including, but not limited to, the United Arab Emirates (UAE), China, Japan, Korea, and in certain regions of Asia and additional services as reasonably requested by the Company during the Term of the Agreement as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued G&amp;P <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240102__20240102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zomGb32pVqf9" title="Number of restricted common shares issued">250,000</span> shares of restricted common stock. G&amp;P was to receive an additional <span id="xdx_90C_ecustom--AdditionalStockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240102__20240102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zeE7tCjL8s5" title="Number of additional restricted common shares issued">500,000</span> shares in 90 days, if the agreement was still in place . The Consulting Shares were issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The agreement contained customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_z109y6wX64d5" title="Shares issued price per share">0.28</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240102__20240102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zVDyud0prLM6" title="Number of restricted common shares issued, value">70,000</span>. The Company issued G&amp;P a total of <span id="xdx_905_ecustom--AdditionalStockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240102__20240102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember_zK1xEDS86EFc" title="Number of additional restricted common shares issued">500,000</span> additional shares and the remaining contract was terminated with no additional shares being owed to G&amp;P.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 10, 2024, we renewed a Consulting Agreement with Luca Consulting, LLC (“<span style="text-decoration: underline">Luca</span>”), to provide certain management and consulting services to the Company during the term of the agreement, which is for three months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240110__20240110__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zyZRwTrchve5" title="Number of restricted common shares issued">200,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement and agreed to pay Luca $<span id="xdx_903_ecustom--AgreementPayableInCash_c20240110__20240110__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zxCcB6Dda5Jb" title="Agreement payable in cash">15,000</span> in cash, payable as follows: <span id="xdx_90D_ecustom--ConsultingAgreementDescription_c20240110__20240110__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zsm3oCr9H109" title="Consulting agreement description">(a) $5,000 on the signing of the agreement; and (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters.</span> The shares were valued at $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240110__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zNlUGJGqHlY4" title="Shares issued price per share">0.28</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240110__20240110__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zyPqIzXh77V1" title="Number of restricted common shares issued, value">56,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 11, 2024, we entered into a Consulting Agreement with First Level Capital (“<span style="text-decoration: underline">First Level</span>”), to provide certain management and consulting services to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach of the agreement by either party. In consideration for agreeing to provide the services under the agreement, the Company issued an initial <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240111__20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zoyO5PO3AAoa" title="Number of restricted common shares issued">250,000</span> shares of the Company’s restricted common stock upon the parties’ entry into the agreement, agreed to issue an additional <span id="xdx_90B_ecustom--AdditionalStockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240111__20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_z3sAFFP8dg47" title="Number of additional restricted common shares issued">250,000</span> shares of the Company’s restricted common stock before the end of the term of the agreement and to pay First Level $<span id="xdx_900_ecustom--AgreementPayableInCash_c20240111__20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_z1zFmFhzO09i" title="Agreement payable in cash">60,000</span> in cash, payable as follows: <span id="xdx_900_ecustom--ConsultingAgreementDescription_c20240111__20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zyvVvqkSrcYc" title="Consulting agreement description">(a) $60,000 on the signing of the agreement; and (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters.</span> The initial shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_z2BFpNZ04Nya" title="Shares issued price per share">0.29</span> per share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240111__20240111__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--FirstLevelCapitalMember_zdkDDbtieQCa" title="Number of restricted common shares issued, value">144,950</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2024, the underwriters in the follow-on offering notified the Company that they were exercising their over-allotment option in full to purchase an additional <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_ztkikB60vKG7" title="Number of shares issued">600,000</span> shares of common stock, which sale closed on January 22, 2024. The net proceeds to the Company from the sale of the <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zaWPmDp4nLyg" title="Number of shares issued">600,000</span> shares of common stock, after deducting underwriting discounts and expenses, was approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zAQGdFz1tAq" title="Proceeds from sale of common stock">160,000</span>. Inclusive of the full exercise of the over-allotment option, a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240118__20240118__srt--TitleOfIndividualAxis__custom--UnderwritersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zt2VMurlEwb2" title="Number of shares issued">4,600,000</span> shares of common stock were issued and sold in the follow-on offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2024, pursuant to the Consulting Agreement with G&amp;P, the Company issued G&amp;P another <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zW3WnI1ThSej" title="Number of restricted common shares issued">250,000</span> shares of restricted common stock. The Consulting Shares were issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The shares were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240207__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zIUjZR9Zhjx4" title="Shares issued price per share">0.41</span> per share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240207__20240207__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--GAndPGeneralConsultingMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_z1T2jpt9bIfb" title="Number of restricted common shares issued, value">102,500</span>. The Company subsequently terminated the Consulting Agreement with G&amp;P and there were no additional shares owed to G&amp;P as a result of the termination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2024, we entered into Amendment to the of January 10, 2024 consulting agreement with Luca, extending the agreement for an additional six months (the “<span style="text-decoration: underline">Luca Amendment</span>”). In consideration for entering into the Luca Amendment, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240321__20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_z5KrCtWtOMl8" title="Number of restricted common shares issued">500,000</span> shares of the Company’s restricted common stock to Luca upon the parties’ entry into the Luca Amendment and agreed to continue to pay Luca $<span id="xdx_904_ecustom--AgreementPayableInCash_c20240321__20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zRaHrgQkOfmd" title="Agreement payable in cash">5,000</span> in in cash on the tenth of each month throughout the remainder of the extended agreement. The shares were valued at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_z9OScmwF7fW" title="Shares issued price per share">0.1975</span> per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240321__20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zXHAKM63JPA4" title="Number of restricted common shares issued, value">98,750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2024, we entered into a Consulting Agreement with Zvonimir Moric, an individual (“<span style="text-decoration: underline">Zee</span>”). Pursuant to the consulting agreement, Zee agreed to provide consulting and general business advisory services as it relates to making introductions to strategic partners to expand the sales of the Company’s products and additional services as reasonably requested by the Company during the Term of the Agreement as reasonably requested by the Company during the term of the agreement, which is for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Zee <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240321__20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_zebao7Gzv80b" title="Number of restricted common shares issued">150,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_zh1vdeqXSdUe" title="Shares issued price per share">0.1975</span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240321__20240321__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--ZvonimirMoricConsultingMember_z1leSBZEWOF7" title="Number of restricted common shares issued, value">29,625</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 8, 2024, the Company entered into an Equity Purchase Agreement with the Purchaser pursuant to which the Purchaser committed to purchase up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240408__20240408__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zMElFAAbRa96" title="Number of shares issued, value">25,000,000</span> of the Company’s common stock. On April 8, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240408__20240408__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zwnZ63RMjhj3" title="Number of shares issued">1,000,000</span> shares of the Company’s common stock to the Purchaser as a commitment fee. The Commitment Shares were valued at $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20240408__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommitmentSharesMember_zALdwX1p8QY6" title="Share price">0.2149</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240408__20240408__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommitmentSharesMember_zyhrE61uBjG2" title="Number of shares issued, value">214,900</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 25, 2024, the Company amended its Consulting Agreement with PHX dated November 7, 2023 whereby the Company agreed to issue PHX an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240425__20240425__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb322PbJ4lN2" title="Number of restricted shares issued">200,000</span> shares of restricted common stock. The additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240425__20240425__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zjiAGmiwG7p2" title="Number of restricted shares issued">200,000</span> shares were issued under, and subject to the terms of, the Company’s 2022 Equity Incentive Plan. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20240425__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zEdFRNAHORtk" title="Share price">0.28</span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240425__20240425__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zsTf3y7ISJgf" title="Number of restricted stock value">56,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between May 21-24, 2024, the Purchaser converted a total of <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240521__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJcEgMHoylrb" title="Number of converted shares">355</span> shares of Series B Preferred Stock into <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240521__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsz71NacRRgi" title="Number of shares issued">1,923,644</span> shares of common stock, in accordance with the terms of the Series B Preferred Stock. The shares were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zW1TUN7Mxeyj" title="Share price">0.203</span> per share for a total value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240521__20240524__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCbyltQvrZZh" title="Number of shares issued value">390,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2024, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zNKZaY8E8ob4" title="Shares new issues">250,000</span> shares of common stock to the Purchaser pursuant to the terms of the ELOC, at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240521__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zlFAMUeHfysk" title="Shares issued price per share">0.48</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zzPDVkoZQgRh" title="Shares new issues value">119,750</span>, before fees, discounts and expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2024, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240522__20240522__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zK8wwzZQgang" title="Shares new issues">700,000</span> shares of common stock to the Purchaser pursuant to the terms of the ELOC, at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20240522__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zVsCw3wWktvd" title="Shares issued price per share">0.48</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240522__20240522__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zLtxb1Ultq5l" title="Shares new issues value">337,915</span>, before fees, discounts and expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2024, we entered into a Consulting Agreement with Acorn Management Partners, L.L.C. (“<span style="text-decoration: underline">Acorn</span>”). Pursuant to the consulting agreement, Acorn agreed to provide consulting and general business advisory services as it relates to making introductions to strategic partners and additional services as reasonably requested by the Company during the term of the Agreement as reasonably requested by the Company during the term of the agreement. In consideration for agreeing to provide the services under the agreement, the Company issued Acorn <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240523__20240523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AcornManagementPartnersLLCMember_zb7rZTlH7GXh" title="Shares issued">192,308</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AcornManagementPartnersLLCMember_z4F7ItpbQCs1" title="Shares issued price per share">0.52</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240523__20240523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AcornManagementPartnersLLCMember_z8YfTCYaMgXd" title="Shares issued value">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2024, the Board of Directors issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240605__20240605__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndEmployeesMember_zcRrMrtrHB0a" title="Shares issued">1,250,000</span> shares to the certain officers, directors and employees of the Company, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240605__20240605__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndChairmanMember_zNP2GMGMwGA8" title="Shares issued">800,000</span> shares issued to Jacob D. Cohen, the Company’s Chief Executive Officer and Chairman, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240605__20240605__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zLxdIBdjR28h" title="Shares issued">100,000</span> shares issued to Amanda Hammer, the Company’s Chief Operating Officer, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240605__20240605__srt--TitleOfIndividualAxis__srt--PresidentMember_z1aU48zdhX8b" title="Shares issued">50,000</span> shares to Efrain Karchmer who serves as the President of MangoRx Mexico, and <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240605__20240605__srt--TitleOfIndividualAxis__custom--ThreeIndependentDirectorsMember_zKwjgv9e2Bzi" title="Shares issued">100,000</span> shares issued to each of the Company’s three independent directors as a bonus for services rendered for 2024. These shares were issued under the Company’s 2022 Equity Incentive Plan and were valued at $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20240605__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zKT8PN6ny9S4" title="Shares issued price per share">0.35</span> per share for a total value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240605__20240605__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zKcsAbK02P6b" title="Shares issued value">437,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company granted a total of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z6z6DR04WoXg" title="Number of options">1,250,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zwVlL9x4Zb9" title="Number of options granted">750,000</span> were granted to Jacob Cohen, the Company’s CEO, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zXo4OVW96rq6" title="Number of options granted">500,000</span> were granted to Jonathan Arango, the Company’s then President and then COO, related to their respective employment agreement. The options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zw5IMoT6mQOj" title="Exercise price">1.10</span> per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8Hd5Yr01oU3" title="Vesting term">three years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zDwcrJ3x79V8" title="Number of options">150,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer, the Company’s COO, related to her employment agreement. The options have an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTEHn7w2HCA8" title="Exercise price">1.10</span> per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230501__20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhYFDY93Lekf" title="Vesting term">three years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2023, the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zQhmLane7Qol" title="Number of options">1,250,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan to Jacob Cohen, the Company’s CEO, related to his employment agreement. The options have an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmU13sU8Xih6" title="Exercise price">0.32</span> per share, an original life of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20231228__20231228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoV3dIGLyLT" title="Vesting term">five years</span> and vested at the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024, Mr. Arango resigned from his position as President and Director of the Company. As detailed in his employment agreement, <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240328_ze97UyQXonDf" title="Number of options unvested">283,333</span> unvested options were forfeited upon resignation or termination of employment as an officer and director. Mr. Arango did not exercise his <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20240628_z9ehptddO5ig" title="Number of options unvested">216,667</span> vested options by the June 28, 2024 deadline resulting in all vested options being forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended June 30, 2024 and 2023, $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630_zB3wi67EPkpj" title="Share based compensation">88,945</span> and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zs3qRPAlZose" title="Share based compensation">131,113</span>, respectively, has been recorded and included as stock-based compensation expense on the consolidated statement of operations. Mr. Cohen, Mr. Arango (former President and Director) and Ms. Hammer are related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z11lMNVQNWJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock option activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztlKGmvT3d3" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zo3ULXhJGa1h" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_zkzLKP3Ymk1k" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z0rVrMmzhI4a" style="width: 16%; text-align: right" title="Options, Granted">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_znibeufAlP9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_z3aUaCdDdQ5g" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3422">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zgfmxkfTEC0b" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3424">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zMqqFIOEKkZc" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl3426">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zjgoaipqZS27" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl3428">-</span></td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired / Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240630_zhgXQpfpF6O4" style="text-align: right" title="Options, Expired">(283,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zvvmRiUdwgQ6" style="text-align: right" title="Weighted Average Exercise Price, Expired">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zuFnJpLxLXP4" style="text-align: right" title="Options, Outstanding Ending Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zqoP3QxsMd3j" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zklizYGpiSQ4" style="text-align: right" title="Options, Exercisable Ending Balance">1,812,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOrlBhf4YUPc" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_zb61JMSQyUTd" style="text-align: right" title="Options, Outstanding Beginning Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20240101__20240630_zM6yNqFUS5e5" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630_zHxI0kooyND1" style="text-align: right" title="Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl3446">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_z5oOJ2fFH6G" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630_ztmo2KH06Hq6" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3450">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zyfk4RMN0AXi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3452">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired / Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240630_zSBsZdvgV9sj" style="text-align: right" title="Options, Expired">(283,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zovUWMi8cyUf" style="text-align: right" title="Weighted Average Exercise Price, Expired">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zqvC9xnv4CMc" style="text-align: right" title="Options, Outstanding Ending Balance">2,366,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630_zp31JPyaxKJc" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.69</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630_zd76c1j0pwk1" style="text-align: right" title="Options, Exercisable Ending Balance">1,979,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630_z4AFsCwzJp2" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.61</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zrUBe6k5Vxag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zPVFTaP1Xj78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for options granted, and exercisable as of June 30, 2024 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B1_zAiWFNAhNDP6" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per<br/> Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise <br/> Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise <br/> Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zbECWVA20teb" style="width: 13%; text-align: right" title="Weighted Average Outstanding">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z5F9a8JbnZz9" style="width: 13%; text-align: right" title="Outstanding Options">1,116,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8svPuRjaNJk" title="Options Term">4.03</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ze9afVk7c43j" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9huE1jF9Ij7" style="width: 13%; text-align: right" title="Exercisable Options">729,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zjxsF6mJUuj2" style="width: 13%; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zR8evZ0XNdy8" style="text-align: right" title="Weighted Average Outstanding">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_za9pcrmZ9zqh" style="text-align: right" title="Outstanding Options">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFiBEzVIYIHg" title="Options Term">4.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2JvQn2NQm9d" style="text-align: right" title="Weighted Average Exercisable Price">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjnFY96lg5L7" style="text-align: right" title="Exercisable Options">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4fxX5KP9Yr4" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.32</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zPAi9XdFE5w5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the fair value of exercisable options outstanding was $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240630_za8UR45fmT38" title="Exercisable options outstanding">811,261</span>. The aggregate initial fair value of the options measured on the grant date of August 31, 2022, May 1, 2023 and December 28, 2023 was calculated using the Black-Scholes option pricing model based on the following assumption:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaQhcnSyjE6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zFKHzK88UvS1" style="display: none">SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__srt--RangeAxis__srt--MaximumMember_zmrWnKxWmLMe" title="Fair value of common stock on measurement date">0.99</span> – <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__srt--RangeAxis__srt--MinimumMember_zHJfEpSaFbb9" title="Fair value of common stock on measurement date">0.29</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zTAhRFjP0lpg" title="Risk free interest rate">3.83</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zYRJJKFgpFTb" title="Risk free interest rate">3.30</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z2gAK9iBsMEl" title="Volatility">232.05</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_z1KYYUVcw2F3" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_zIceIz67O9vi" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zkmUI3MYes0d" title="Expected term">6.0</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zKjGVfFwIH48" title="Expected term">3.5</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, in accordance with staff accounting bulletin (“<span style="text-decoration: underline">SAB</span>”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term</span></td></tr> </table> <p id="xdx_8A4_zMFR3js2zpmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, the Company initiated a private placement of up to $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn6n6_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zEfqb9ikTgXh" title="Warrants to purchase">2</span> million of units to accredited investors, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zwn0lhSdTFG9" title="Shares price per share">1.00</span> per unit (the “Private Placement Warrants”). The warrants have a five-year term (from each closing date that units were sold) and an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220831__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zUlwx7Hfutq9" title="Warrants exercise price per share">1.00</span> per share. In total, we sold an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220816__20221222__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__srt--TitleOfIndividualAxis__custom--TwentyThreeAccreditedInvestorsMember_zO7lbWLFulK6" title="Number of shares issued">2,000,000</span> units for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220816__20221212__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__srt--TitleOfIndividualAxis__custom--TwentyThreeAccreditedInvestorsMember_zDKj2HCCun2k" title="Number of shares issued value">2,000,000</span> to 23 accredited investors between August 16, 2022 and December 22, 2022. There were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zUMedRaBzE1a" title="Exercise of warrants shares">975,500</span> and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember_zgsOBy0fFNKb" title="Exercise of warrants shares">975,500</span> Private Placement Warrants outstanding as of June 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zHM1J58FDmC1" title="Warrants issued">87,500</span> shares of common stock with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsDw19o0PMW8" title="Exercise price">5.00</span> per share, which were exercisable six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpLBucCJwYgd" title="Fair value of warrants">31,995</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As additional consideration in connection with the follow-on offering, upon the closing of the follow-on offering, we granted Boustead Securities, LLC, the representative of the underwriters named in the Underwriting Agreement for the secondary offering, warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2cM0r9RppNf" title="Warrants issued">280,000</span> shares of common stock with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDTyGxayl1k3" title="Exercise price">0.38</span> per share, which were exercisable six months after the effective date of the registration statement filed in connection with the follow-on offering (December 19, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20231219__20231219__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRO0GXG0NJz9" title="Fair value of warrants">78,174</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2024, pursuant to the Underwriting Agreement, the Company also issued a common stock purchase warrant to the representative of the underwriters for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHMFHJZe97c7" title="Number of warrants to purchase of common stock">42,000</span> shares of its common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zjaqcKQ0Zv4g" title="Exercise price per share">0.375</span>, subject to adjustments. The warrants are exercisable at any time and from time to time, in whole or in part, until December 14, 2028, and may be exercised on a cashless basis. The warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the warrants. The warrants and the shares of common stock underlying the warrants were registered as a part of the follow-on registration statement. The fair value of the warrants on the grant date was $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240122__20240122__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zeXI0z3cOMU3" title="Fair value of warrants">12,086</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2024, pursuant to the SPA with the Purchaser, the Company issued a common stock purchase warrant for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhNyKq8gi9A5" title="Warrants to purchase common stock">3,300,000</span> shares of its common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrXlhJOLtBq5" title="Exercise price per share">0.26</span> per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until April 4, 2029. The fair value of the warrant on the grant date was $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfaHgtBhSD58" title="Fair value of warrants">681,352</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX2NKScY56xa" title="Number of shares issued upon exercise">1,000,000</span> shares of its common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI933uz8Stlc" title="Exercise price per share">0.50</span> per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until June 28, 2029. The fair value of the warrant on the grant date was $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgrFmxLInHHe" title="Fair value of warrants">260,750</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28 2024, pursuant to the SPA (as amended), the Company issued a common stock purchase warrant for the purchase of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zXF2SZScCWk8" title="Number of shares issued upon exercise">500,000</span> shares of its common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_znzNJRQcOh5b" title="Exercise price per share">1.00</span> per share to the Purchaser. The warrant is exercisable at any time and from time to time, in whole or in part, until June 28, 2029. The fair value of the warrant on the grant date was $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20240628__20240628__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zV2PDYxXgnGa" title="Fair value of warrants">122,341</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024 and December 31, 2023, the fair value of warrants outstanding was $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zwv91qwE8zZ3" title="Fair value of warrants outstanding">1,735,966</span> and $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrKC6PleH7Bf" title="Fair value of warrants outstanding">852,480</span>, respectively. Because the warrants vested immediately, the fair value was assessed on the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgFkWiTlE3Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock warrants activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zyRnbGSxnhFc" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted </b></span><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6ZN3ugDFli7" style="width: 16%; text-align: right" title="Warrants Beginning Balance">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4diokqW8aI5" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Beginning Balance">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOie2vQt1Gb" style="text-align: right" title="Warrants Granted">367,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd7kLXFwvqob" style="text-align: right" title="Weighted Average Exercise Price Granted">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAMs0f73yiGf" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV5ErWiKE9g3" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z57aykE1gMG" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrFwYCHDH0a1" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl3584">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoVUICsaWfFa" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3586">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFcGh3X14RMa" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3588">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWJPMZi75Mm3" style="text-align: right" title="Warrants Outstanding, Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqDbk9BjgiT1" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKSewzZODLL7" style="text-align: right" title="Warrants Exercisable Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHpxKqsUnyh" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.41</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDHqLoh2X07h" style="text-align: right" title="Warrants Beginning Balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4H8aD52LAC5" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlOu5RlfbqL8" style="text-align: right" title="Warrants Granted">4,842,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGO2JDMe3OF2" style="text-align: right" title="Weighted Average Exercise Price Granted">0.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj2hZw2QVjUi" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3606">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqVjKGheavDl" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3608">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj7Foc6aGcsa" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl3610">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zogPMvy1Nvde" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl3612">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z16bkQ1cs6m1" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3614">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjhyGtNmyos" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3616">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVBZ44jlS3oe" style="text-align: right" title="Warrants Outstanding, Ending balance">6,185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3VaLpUm6nd9" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRJgKb2bv8Uj" style="text-align: right" title="Warrants Exercisable Ending balance">6,185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSG9QNQaelj" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">0.55</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zEYciED7rJK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfWarrantsPlansByExercisePriceRangeTextBlock_zwzQg4Aj9vz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of June 30, 2024, were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zeFZJiy412Qh" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; vertical-align: bottom"></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average<br/> Warrant<br/> Exercise Price<br/> Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Life (Years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630_zDbALKfwrYe5" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised">0.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20240630_zwGvjv6rnCYk" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">6,185,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20240101__20240630_zmDKyeLSER3e" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">4.30</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zF8nMMVRt6i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, warrants to purchase <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLtbtLyFW1pj" title="Warrants outstanding">6,185,000</span> shares of common stock are outstanding and vested, and the vested stock warrants have a weighted average remaining life of <span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3WPxcoIhl7" title="Outstanding and vested warrants expected term">4.30</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfWarrantsValuationAssumptionsTableTextBlock_zFBdMPwRwE2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B7_zVVxOSp2fJfd" style="display: none">SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z3uGpk3jSihk" title="Fair Value of Common Stock on measurement date">0.21</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2hFNc6ZwV83" title="Fair Value of Common Stock on measurement date">0.73</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJeYD6ZR0yl4" title="Risk-free interest rate">2.95</span>% to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zr7YTbESUGl4" title="Risk-free interest rate">4.38</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFSRG0cpFKu3" title="Volatility">81.92</span>% to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYzkZZaTU8G8" title="Volatility">239.06</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm8LQWHc2pXk" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCEz8eboYiF5" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</span></td></tr> </table> <p id="xdx_8A0_zX1meSp59wak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 0.0001 6000 0.0001 1100 2145 2145 0 0 1500 1650000 3300000 1500000 500 500000 150000 150 100000 100 <p id="xdx_899_ecustom--ScheduleOfSharesPurchaseAgreementTableTextBlock_zJEn1AdNZ5l1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2024, the Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1, which amended the SPA to, adjust the closings which were to take place under the SPA as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zFYw4ERUi8J2" style="display: none">SCHEDULE OF SHARE PURCHASE AGREEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">#</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Initial Stated<br/> Value of<br/> Preferred<br/> Stock to be<br/> issued by<br/> installment</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Warrants<br/> to be issued</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Closing Date</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Aggregate<br/> Purchase<br/> Price by<br/> installment<br/> (USD)</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 12%; text-align: left">Initial Closing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zyfzRbK2slHi" style="width: 12%; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">550,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zzmtcwfSMy55" style="width: 12%; text-align: right" title="Warrants to be issued">3,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td id="xdx_98C_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--InitialClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zf5MmTqv8wx4" style="width: 38%; text-align: justify" title="Closing Date">Initial Closing Date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--InitialClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zEdR7zuK4Bbi" title="Aggregate Purchase Price by installment">500,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zqLiMwYXQVG" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td id="xdx_988_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--SecondClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z6JllAXYxKha" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zcGP3rqTJiJ3" title="Aggregate Purchase Price by installment">250,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Third Closing</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zJviH2RByN28" style="text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zylka7ttZUl2" style="text-align: right" title="Warrants to be issued">1,500,000</td><td style="text-align: left"> </td><td> </td> <td id="xdx_989_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zQDhkLl0Mb5h" style="text-align: justify" title="Closing Date">On or before June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ThirdClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z6i1mL6NejZ8" title="Aggregate Purchase Price by installment">750,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Fourth Closing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zPCUssFGmN8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">1,100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_ecustom--SharePurchaseAgreementDescription_c20240428__20240428__us-gaap--AwardTypeAxis__custom--FourthClosingMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zzVb1vLWbP2j" style="text-align: justify; padding-bottom: 1.5pt" title="Closing Date">Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--FourthClosingMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zJE3iLFtnc38" title="Aggregate Purchase Price by installment">1,000,000.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockValue_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_z2CnNNqY51Lj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Initial Stated Value of Preferred Stock to be issued by installment">2,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zCkFgasphune" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants to be issued">4,800,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_ecustom--AggregatePurchasePriceByInstallmentAmount_iI_c20240428__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PurchaserMember_zlQ6Iz2F5ZC" title="Aggregate Purchase Price by installment">2,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 550000 3300000 Initial Closing Date 500000 275000 On or before June 30, 2024 250000 825000 1500000 On or before June 30, 2024 750000 1100000 Such date as is no later than 180 days after the shares of Common Stock issuable in respect of the Series B Preferred Stock sold in each of the Initial Closing, Second Closing, the Third Closing, and the Fourth Closing have been registered under the Securities Act, subject to any limitations pursuant to Rule 415 1000000.00 2750000 4800000 2500000 750 1000000 0.50 500000 1.00 1000 50 55000 270936 0.203 155 170500 839901 0.203 150 165000 812807 0.203 6250000 0.0001 980000 980000 0 0 20000000 980000 20.00 19600000 400000 (i) with $200,000 payable on or before June 30, 2024, (ii) $100,000 payable on or before August 31, 2024, and (iii) $100,000 payable on or before November 30, 2024. 200000000 200000000 0.0001 0.0001 29135451 29135451 21419500 21419500 100000 50000 1.00 100000 250000 1.00 250000 25000 2000 1.00 25000 25000 1.00 25000 the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Mr. Haroon and Ms. Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company’s successful launch of a new product category, and 50,000 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Mr. Helfrich and Mr. Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company’s successful launch of a new product category, and 7,500 shares upon the Company’s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. 1.00 350000 1250000 4.00 5000000 100000 1.00 100000 100000 1.00 100000 25000 1.00 25000 25000 1.00 25000 75000 1.00 75000 100000 1.00 100000 25000 1.00 25000 150000 The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, under the Company’s 2022 Equity Incentive Plan (the “Plan”), with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $1.00 per share, with options to purchase 50,000 shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and Mrs. Hammer. 1.00 50000 300000 180000 1.00 180000 50000 1.10 55000 20000 1.10 22000 50000 5000 1.10 55000 25000 1.00 25000 150000 1.00 150000 75000 1.00 75000 24500 1.00 24500 100000 1.00 100000 100000 1.00 100000 100000 1.00 100000 75000 40000 (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before March 31, 2024 1.13 84750 50000 2000 200000 15000 (a) $5,000 on the signing of the agreement; (b) $5,000 on the tenth of each month throughout the remainder of the agreement. 0.63 126000 10000 30000 0.58 17400 50000 0.58 29000 200000 0.47 94000 100000 0.58 58000 4000000 0.30 1200000 250000 500000 0.28 70000 500000 200000 15000 (a) $5,000 on the signing of the agreement; and (b) $5,000 on the tenth of each month throughout the remainder of the agreement. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify Luca and its affiliates with regard to certain matters. 0.28 56000 250000 250000 60000 (a) $60,000 on the signing of the agreement; and (b) $60,000 on the approval by the Company. The Service Agreement includes customary indemnification obligations requiring the Company to indemnify First Level and its affiliates with regard to certain matters. 0.29 144950 600000 600000 160000 4600000 250000 0.41 102500 500000 5000 0.1975 98750 150000 0.1975 29625 25000000 1000000 0.2149 214900 200000 200000 0.28 56000 355 1923644 0.203 390500 250000 0.48 119750 700000 0.48 337915 192308 0.52 100000 1250000 800000 100000 50000 100000 0.35 437500 1250000 750000 500000 1.10 P3Y 150000 1.10 P3Y 1250000 0.32 P5Y 283333 216667 88945 131113 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z11lMNVQNWJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock option activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztlKGmvT3d3" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zo3ULXhJGa1h" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231_zkzLKP3Ymk1k" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_z0rVrMmzhI4a" style="width: 16%; text-align: right" title="Options, Granted">1,400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_znibeufAlP9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_z3aUaCdDdQ5g" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3422">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zgfmxkfTEC0b" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3424">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20231231_zMqqFIOEKkZc" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl3426">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231_zjgoaipqZS27" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl3428">-</span></td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired / Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240630_zhgXQpfpF6O4" style="text-align: right" title="Options, Expired">(283,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zvvmRiUdwgQ6" style="text-align: right" title="Weighted Average Exercise Price, Expired">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zuFnJpLxLXP4" style="text-align: right" title="Options, Outstanding Ending Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zqoP3QxsMd3j" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zklizYGpiSQ4" style="text-align: right" title="Options, Exercisable Ending Balance">1,812,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231_zOrlBhf4YUPc" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630_zb61JMSQyUTd" style="text-align: right" title="Options, Outstanding Beginning Balance">2,650,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20240101__20240630_zM6yNqFUS5e5" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630_zHxI0kooyND1" style="text-align: right" title="Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl3446">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_z5oOJ2fFH6G" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl3448">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630_ztmo2KH06Hq6" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3450">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zyfk4RMN0AXi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3452">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired / Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240101__20240630_zSBsZdvgV9sj" style="text-align: right" title="Options, Expired">(283,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630_zovUWMi8cyUf" style="text-align: right" title="Weighted Average Exercise Price, Expired">1.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630_zqvC9xnv4CMc" style="text-align: right" title="Options, Outstanding Ending Balance">2,366,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630_zp31JPyaxKJc" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">0.69</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630_zd76c1j0pwk1" style="text-align: right" title="Options, Exercisable Ending Balance">1,979,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630_z4AFsCwzJp2" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">0.61</td><td style="text-align: left"> </td></tr> </table> 1250000 1.10 1400000 0.40 283333 1.10 2650000 0.73 1812500 0.73 2650000 0.73 283333 1.10 2366667 0.69 1979167 0.61 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zPVFTaP1Xj78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for options granted, and exercisable as of June 30, 2024 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B1_zAiWFNAhNDP6" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per<br/> Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise <br/> Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise <br/> Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zbECWVA20teb" style="width: 13%; text-align: right" title="Weighted Average Outstanding">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z5F9a8JbnZz9" style="width: 13%; text-align: right" title="Outstanding Options">1,116,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8svPuRjaNJk" title="Options Term">4.03</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ze9afVk7c43j" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price">1.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9huE1jF9Ij7" style="width: 13%; text-align: right" title="Exercisable Options">729,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zjxsF6mJUuj2" style="width: 13%; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zR8evZ0XNdy8" style="text-align: right" title="Weighted Average Outstanding">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_za9pcrmZ9zqh" style="text-align: right" title="Outstanding Options">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFiBEzVIYIHg" title="Options Term">4.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2JvQn2NQm9d" style="text-align: right" title="Weighted Average Exercisable Price">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjnFY96lg5L7" style="text-align: right" title="Exercisable Options">1,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_uUSDPShares_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4fxX5KP9Yr4" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.32</td><td style="text-align: left"> </td></tr> </table> 1.10 1116667 P4Y10D 1.10 729167 1.10 0.32 1250000 P4Y6M 0.32 1250000 0.32 811261 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zaQhcnSyjE6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zFKHzK88UvS1" style="display: none">SCHEDULE OF OPTIONS FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__srt--RangeAxis__srt--MaximumMember_zmrWnKxWmLMe" title="Fair value of common stock on measurement date">0.99</span> – <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__srt--RangeAxis__srt--MinimumMember_zHJfEpSaFbb9" title="Fair value of common stock on measurement date">0.29</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zTAhRFjP0lpg" title="Risk free interest rate">3.83</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zYRJJKFgpFTb" title="Risk free interest rate">3.30</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z2gAK9iBsMEl" title="Volatility">232.05</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_z1KYYUVcw2F3" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_zIceIz67O9vi" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zkmUI3MYes0d" title="Expected term">6.0</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zKjGVfFwIH48" title="Expected term">3.5</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, in accordance with staff accounting bulletin (“<span style="text-decoration: underline">SAB</span>”)14-D.2, used the simplified method (plain vanilla) to determine the overall expected term</span></td></tr> </table> 0.99 0.29 0.0383 0.0330 2.3205 0.9254 0 P6Y P3Y6M 2000000 1.00 1.00 2000000 2000000 975500 975500 87500 5.00 31995 280000 0.38 78174 42000 0.375 12086 3300000 0.26 681352 1000000 0.50 260750 500000 1.00 122341 1735966 852480 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgFkWiTlE3Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes common stock warrants activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zyRnbGSxnhFc" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted </b></span><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6ZN3ugDFli7" style="width: 16%; text-align: right" title="Warrants Beginning Balance">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4diokqW8aI5" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Beginning Balance">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOie2vQt1Gb" style="text-align: right" title="Warrants Granted">367,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd7kLXFwvqob" style="text-align: right" title="Weighted Average Exercise Price Granted">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAMs0f73yiGf" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV5ErWiKE9g3" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z57aykE1gMG" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl3582">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrFwYCHDH0a1" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl3584">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoVUICsaWfFa" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3586">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFcGh3X14RMa" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3588">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWJPMZi75Mm3" style="text-align: right" title="Warrants Outstanding, Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqDbk9BjgiT1" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKSewzZODLL7" style="text-align: right" title="Warrants Exercisable Ending balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHpxKqsUnyh" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.41</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td>Outstanding, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDHqLoh2X07h" style="text-align: right" title="Warrants Beginning Balance">1,343,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4H8aD52LAC5" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlOu5RlfbqL8" style="text-align: right" title="Warrants Granted">4,842,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGO2JDMe3OF2" style="text-align: right" title="Weighted Average Exercise Price Granted">0.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj2hZw2QVjUi" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3606">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqVjKGheavDl" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl3608">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj7Foc6aGcsa" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl3610">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zogPMvy1Nvde" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl3612">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z16bkQ1cs6m1" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3614">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjhyGtNmyos" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl3616">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVBZ44jlS3oe" style="text-align: right" title="Warrants Outstanding, Ending balance">6,185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3VaLpUm6nd9" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRJgKb2bv8Uj" style="text-align: right" title="Warrants Exercisable Ending balance">6,185,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTSG9QNQaelj" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">0.55</td><td style="text-align: left"> </td></tr> </table> 2000000 1.00 367500 1.22 -1024500 1.00 1343000 1.41 1343000 1.41 1343000 1.41 4842000 0.39 6185000 0.55 6185000 0.55 <p id="xdx_89A_ecustom--ScheduleOfWarrantsPlansByExercisePriceRangeTextBlock_zwzQg4Aj9vz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average exercise prices, remaining lives for warrants granted, and exercisable as of June 30, 2024, were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zeFZJiy412Qh" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; vertical-align: bottom"></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average<br/> Warrant<br/> Exercise Price<br/> Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Life (Years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20240630_zDbALKfwrYe5" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised">0.55</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20240630_zwGvjv6rnCYk" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">6,185,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20240101__20240630_zmDKyeLSER3e" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">4.30</td><td style="width: 1%; text-align: left"> </td></tr> </table> 0.55 6185000 P4Y3M18D 6185000 P4Y3M18D <p id="xdx_89F_ecustom--ScheduleOfWarrantsValuationAssumptionsTableTextBlock_zFBdMPwRwE2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B7_zVVxOSp2fJfd" style="display: none">SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z3uGpk3jSihk" title="Fair Value of Common Stock on measurement date">0.21</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2hFNc6ZwV83" title="Fair Value of Common Stock on measurement date">0.73</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zJeYD6ZR0yl4" title="Risk-free interest rate">2.95</span>% to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zr7YTbESUGl4" title="Risk-free interest rate">4.38</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFSRG0cpFKu3" title="Volatility">81.92</span>% to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYzkZZaTU8G8" title="Volatility">239.06</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm8LQWHc2pXk" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCEz8eboYiF5" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading volatility was determined by calculating the volatility of the Company’s peer group.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not expect to pay a dividend in the foreseeable future.</span></td></tr> </table> 0.21 0.73 0.0295 0.0438 0.8192 2.3906 0 P5Y <p id="xdx_809_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zypkIe66Tg31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_828_zfVSUWagZjl3">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying condensed consolidated financials, the Company had a net loss of $<span id="xdx_90A_eus-gaap--ProfitLoss_iN_di_c20240101__20240630_zpu5ZhFNuIr4" title="Net loss">4,758,936</span> for the six months ended June 30, 2024 and an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240630_zGQm7jZ3DPi8" title="Accumulated deficit">15,986,733</span> as of June 30, 2024. The Company will need to raise additional capital to successfully execute its business plan of which there can be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -4758936 -15986733 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zblBG4fhNW38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_82D_zFXu4U0Bni9">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business. The Company is not currently subject to any such litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a lease for an office in Dallas, Texas classified as operating leases under ASC 842.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway, L.P. (the “<span style="text-decoration: underline">Landlord</span>”) to lease and occupy approximately 2,201 square feet of office space located at 15110 Dallas Parkway, Suite 600, Dallas, Texas 75248 to serve as the Company’s main headquarters (the “<span style="text-decoration: underline">Lease Agreement</span>”). <span id="xdx_909_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928_zHedTlj6cFRe" title="Operating lease, description">The Lease Agreement has a term of thirty-eight (<span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_z6AiGuaBNWJa" title="Lease term">38</span>) months and has a monthly base rent of $<span id="xdx_90F_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928_zED1sj7jhYde" title="Base rent">5,777.63</span>, or $31.50 per square foot, from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term</span> (the “<span style="text-decoration: underline">Base Rent</span>”). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_907_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zxPqlKMKD84c" title="Percentage of proportionate rent">2.45</span>% (the “<span style="text-decoration: underline">Proportionate Rent</span>”). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month’s Base Rent along with a security deposit equal to $<span id="xdx_904_eus-gaap--PaymentsForRent_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z7EbxtPRdXgh" title="Base rent">16,942</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of <span id="xdx_903_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_ztZ1BjryzjMd" title="Percentage of incremental borrowing rate">8</span>% to estimate the present value of the right-of-use liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has right-of-use assets of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20240630_zlPMFwEPjepi" title="Operating lease, right-of-use asset">90,011</span> and operating lease liabilities of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_c20240630_zBpiMd3Mg9U9" title="Operating lease, liability">97,545</span> as of June 30, 2024. Operating lease expense for the six months ended June 30, 2024 was $<span id="xdx_90C_eus-gaap--OperatingLeaseCost_c20240101__20240630_zbnIDVTYqNuc" title="Operating lease, cost">16,492</span>. The Company has recorded $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20240101__20240630_z33jNkxflnZb" title="Asset impairment charges">0</span> in impairment charges related to right-of-use assets during the six months ended June 30, 2024 .</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zaWPRoqyHCWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B6_zOxWnRyMvNXg" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities at June 30, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20240630_zgGNjDC3PD55" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzowI_zlHWzE149Qii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zeTev8M4R8Hl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,589</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zDBnGDhgssfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,539</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zONX9S4IOfM7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zMGZKYAAsRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z4sBJXrBEf6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The Lease Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term P38M 5777.63 0.0245 16942 0.08 90011 97545 16492 0 <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zaWPRoqyHCWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B6_zOxWnRyMvNXg" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Maturity of Lease Liabilities at June 30, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20240630_zgGNjDC3PD55" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzowI_zlHWzE149Qii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzowI_zeTev8M4R8Hl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,589</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zDBnGDhgssfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,539</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zONX9S4IOfM7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zMGZKYAAsRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,545</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 35950 67589 103539 5994 97545 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zE0MXYYHDop" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 –<span id="xdx_82D_zupuVKINdns2"> SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates events that have occurred after the condensed consolidated balance sheet date but before the condensed consolidated financial statements are issued. Based on the evaluation, the Company identified the following subsequent events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 8, 2024, <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240708__20240708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zE847utTC2Uh" title="Number of shares sold">135</span> shares of Series B Preferred Stock (with an aggregate stated value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240708__20240708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjSho7mDGVfe" title="Aggregate stated value">148,500</span>) were converted by the holder into <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20240708__20240708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2gjrRdA7uvh" title="Conversion of stock shares converted">536,682</span> shares of common stock at a conversion price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240708__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF00szsWoike" title="Conversion price per share">0.2767</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 9, 2024, the Company entered into a Master Distribution Agreement with ISFLST, Inc. (“<span style="text-decoration: underline">ISFLST</span>”) dated July 2, 2024 (the “<span style="text-decoration: underline">Distribution Agreement</span>”). Pursuant to the Distribution Agreement, we agreed to sell, and ISFLST agreed to purchase, certain of our products, including our MangoRx Grow and Mango ED products (collectively, the “<span style="text-decoration: underline">Products</span>”), for distribution and resale by ISFLST during the term of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Distribution Agreement, ISFLST agreed to use commercially reasonable efforts to sell and promote the sale of the Products in Asia Pacific and Latin America (excluding Mexico), and we provided ISFLST a non-exclusive, non-transferable license to market and sell the Products, and grant sub-licenses (subject to certain pre-requisites and limitations described in greater detail in the Distribution Agreement) to sell the Products, in the Market. We also agreed, subject to certain future mutually agreed milestones that ISFLST could earn exclusive rights to market the Products in the applicable “<span style="text-decoration: underline">Market</span>”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Distribution Agreement has a term of three years and is automatically renewable thereafter for three additional one year terms, unless either party provides the other notice of non-renewal at least 90 days prior to an automatic renewal date. The agreement may also be terminated by the non-breaching party upon the material breach of the agreement by the counterparty and failure to cure such breach after 90 days written notice, or upon insolvency.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Distribution Agreement includes customary confidentiality requirements of the parties, representations and warranties of the parties, mutual indemnification rights, disclaimers of warranties and limitation of liabilities, and force majeure provisions The Distribution Agreement also includes a non-solicitation obligation of ISFLST, which applies during the term of the agreement and for two years thereafter. All pricing information will be mutually agreed to by the parties and set forth in a separate purchase order, subject to availability and volume requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 25, 2024, <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240725__20240725__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBwOHe1Elfa4" title="Number of shares sold">10</span> shares of Series B Preferred Stock (with an aggregate stated value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240725__20240725__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztBTiemjmyUg" title="Aggregate stated value">11,000</span>) were converted into <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20240725__20240725__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWzULTwrXt86" title="Conversion of stock shares converted">33,670</span> shares of common stock at a conversion price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20240725__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znLLVi29qg07" title="Conversion price per share">0.3267</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On July 30, 2024, we entered into a Consulting Agreement with John Dorsey, an individual (“Dorsey”). Pursuant to the consulting agreement, Dorsey agreed to provide certain marketing and general related services as it relates expanding the sales of the Company’s products and additional services as reasonably requested by the Company during the Term of the Agreement, which is for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide <span id="xdx_905_eus-gaap--CommonStockConversionFeatures_c20240730__20240730__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--JohnDorseyMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPV6TlMqPmH2" title="Settlement description">the services under the agreement, the Company agreed to pay Dorsey $6,000 a month and issued Dorsey a total of 200,000 shares, which vest in accordance with the following vesting schedule; a) 50,000 shares vest upon the execution of the Agreement, b) 75,000 shares vest upon the three (3) month anniversary of the Agreement, and c) 75,000 shares vest upon the six (6) month anniversary of the Agreement (the “Dorsey Consulting Shares”).</span> Any Dorsey Consulting Shares not vested as described above are to be promptly returned to the Company by the Consultant for cancellation. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240730__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWj56FiOyfd6" title="Share price">0.4209</span> per share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240730__20240730__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3tUhubovU2c" title="Shares issued value">84,180</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company further agreed to issue Dorsey an additional <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__srt--TitleOfIndividualAxis__custom--JohnDorseyMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNWQ1KhZf2A4" title="Number of shares issued">200,000</span> shares of common stock upon Dorsey assisting the Company in obtaining greater than 3500 subscribers for its Prime oral testosterone replacement therapy medications.</span></p> 135 148500 536682 0.2767 10 11000 33670 0.3267 the services under the agreement, the Company agreed to pay Dorsey $6,000 a month and issued Dorsey a total of 200,000 shares, which vest in accordance with the following vesting schedule; a) 50,000 shares vest upon the execution of the Agreement, b) 75,000 shares vest upon the three (3) month anniversary of the Agreement, and c) 75,000 shares vest upon the six (6) month anniversary of the Agreement (the “Dorsey Consulting Shares”). 0.4209 84180 200000